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Abstract 
 
Tumours have been shown to have a number of mechanisms to suppress immunosurveillance 
allowing them to survive and grow. One of these mechanisms involves expression of 
molecules which inhibit T cells such as the molecules involved in the PD-1 pathway. PD-1 is 
expressed on activated T cells and one of its ligands, PD-L1 has been shown to be expressed 
on a wide range of cell types including antigen presenting cells (APCs), endothelial cells as 
well as tumour cells. This pathway is important in maintaining T cell tolerance and 
homeostasis and as a result we hypothesised that this pathway may be an important target for 
immunotherapy in ovarian cancer. 
Ascites and blood from patients with ovarian cancer were collected over a two year period 
and analysis into the phenotype of immune cells and the cytokine content of the ascites was 
carried out. The major finding during this analysis was that APCs from ascites and blood of 
patients with malignant cancer showed a significantly higher level of PD-L1 than on APCs 
from patients with benign/borderline cancer. Furthermore the monocytes from ascites could 
suppress T cell proliferation in a co-culture which could be partially reversed when blocking 
PD-1. The cytokine content of the tumour revealed high levels of immunosuppressive (TGF-
β and IL-10 correlated with malignancy) and pro-angiogenic cytokines which may contribute 
to the suppression of T cell proliferation observed when stimulated T cells were cultured in 
the ascites supernatant. These cytokines may also be responsible for the upregulation of PD-
L1 observed on normal blood monocytes following culture in the ascites supernatant. Real 
time PCR analysis of tumour mass mRNA revealed higher levels of PD-L1 in borderline and 
malignant mRNA compared to normal ovary and flow cytometry showed that PD-L1 is 
expressed on ovarian cancer cell lines of serous histology.  
The second part of this project concentrated on the cloning of a PD-1 KDEL construct. PD-1 
KDEL was to be used as a novel mechanism to down regulate PD-1 ligands on ovarian 
cancer cell lines. The construct was not successful in knocking down expression of PD-L1 on 
cancer cell lines and reasons were put forward for this lack of functionality. Each reason was 
tested experimentally and a hypothesis is put forward as to the reason of its lack of function. 
Alternatives to PD-1 KDEL were also tested. 
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1. INTRODUCTION 
1.1. Cancer 
Cancer is uncontrolled cellular growth leading to a heterogeneous mass of clones each 
distinct in the various mutations they contain. Genetic instability is a hallmark of cancer 
and is caused by genetic and environmental insults leading to the complete loss of growth 
control (Hanahan and Weinberg, 2000). The immune system was proposed to have a role 
in the surveillance of tumour growth and in healthy individuals this ongoing surveillance 
is thought to protect us against cancer (Burnet, 1970). Macfarlane Burnet proposed that 
the immune system recognises the tumour as foreign (even though it is derived from our 
own cells) due to the presence of tumour antigens, whereas Thomas took the view that 
highly evolved species such as humans must have developed strategies to combat cancer 
growth (Burnet, 1970). However the immune system involvement in cancer was plunged 
into controversy following experimental evidence that nude mice (athymic so lack of 
antibody and cellular responses) do not develop an increased number of malignancies 
(Stutman, 1974, 1979). If the mouse doesn’t have a functioning immune system then why 
isn’t it more susceptible to tumour growth? This nude mouse experiment was later solved 
by the understanding that nude mice still have a partially functioning immune system and 
that the study time was not long enough to observe spontaneous tumours (Maleckar and 
Sherman, 1987). Later experiments also strengthened the case for immune involvement, 
these are discussed below. 
 
Knock-out (KO) mice have been instrumental for providing evidence for immune 
surveillance and in the elucidation of the exact nature of the immune effector 
 15 
 
mechanisms. RAG KO mice show an increased susceptibility to carcinogen (MCA) 
induced carcinomas, as well as spontaneous tumours (Shankaran et al., 2001). Two other 
important mice are the interferon (IFN) γ receptor KO mouse which shows increased 
number of tumours, suggesting IFNγ is an important immune mechanism for inhibition of 
tumour growth (suggesting a specific role for CTLs and Th1 cells), and the perforin KO 
mouse which develop more spontaneous and induced tumours than their wild type 
counterparts (Dighe et al., 1994; van den Broek et al., 1996). The latter mouse indicates a 
clear role for CTLs and NK cells in immune surveillance. Many more KO models have 
been produced and indicate a role for both the innate and adaptive arms of the immune 
system in the surveillance of tumours (Dunn et al., 2004). This immune involvement is 
not only seen in mouse models, immunocompromised humans (artificial 
immunosuppression following transplantation as well as virally induced 
immunosuppression e.g. HIV) show an increase of both viral and spontaneous tumours 
e.g. Karposi’s sarcoma frequency is increased amongst HIV infected people (Beral et al., 
1990). 
 
The tumour immunosurveillance theory has been modified recently to include the 
mechanisms by which tumours escape immune recognition. The immunoediting theory 
states that there are 3 phases to tumour growth; elimination by the immune response 
(immunosurveillance), equilibrium and then tumour escape (Dunn et al., 2002). The 
theory states that the immune response “sculpts” the tumour by enforcing a selective 
pressure favouring those tumour clones best equipped to survive the elimination phase. 
This immunoediting means that resistant tumour clones are likely to survive immune 
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attack and an altered version of the tumour will be present which the immune system 
cannot clear. This is the stage when the tumour usually presents itself clinically and 
where there is need for therapeutic intervention.  
 
1.2. Tumour Antigens 
The immune system recognises tumour through recognition of tumour associated 
antigens (TAA) which exist in many forms. Although tumours arise from self cells, the 
altered expression of genes resulting from genetic instability of the tumour results in 
abnormal antigens being presented on the tumour cell compared to the originating cell 
type (Boon et al., 1997). Tumours may express antigen which is specific to tumour cells 
through point mutations of normal genes leading to new epitopes presented on MHC 
class I molecules. Specifically to tumours derived from B and T lymphocytes are 
idiotypic antigens which are a result of the unique antigen receptors expressed by both 
types of cell (Hough et al., 1976). A second class of tumour antigen may arise from 
expression of germ cell genes (De Smet et al., 1999). These are specifically expressed by 
germ line cells and are not presented to the immune system, tumorigenesis may result in 
expression of these genes on the tumour cell which will be presented to the immune 
system via MHC class I. Examples of this include the MAGE-1 and 3 antigens in 
melanoma and breast cancers (Chaux et al., 1999). Alternatively the tumour may 
overexpress differentiation antigens such as tyrosinase which is involved in the 
production of melanin and is overexpressed in melanoma (Brichard et al., 1993). Another 
class of tumour antigen would arise from aberrant post-translational modification such as 
the underglycosylation of the mucin MUC-1 in breast and pancreatic cancer (Nishimori et 
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al., 1994). A final type of tumour antigen would exist in those tumours which are caused 
by a viral infection. This would lead to the presentation of viral oncogenes which would 
be recognised as foreign by the immune response such as the E6 and E7 proteins 
expressed following human papilloma virus infection in cervical cancer (Bleul et al., 
1991). 
 
Although there are many TAA which may result in the recognition of the tumour by the 
immune system, there is rarely a spontaneous regression of the tumour (Dunn et al., 
2002). This is due to other factors in the tumour environment which lead to tumour 
immune evasion. 
 
1.3. Tumour immune evasion 
The immunoediting theory described above states that it is inevitable that certain clones 
from the tumour mass will survive the initial immune system onslaught. These will be the 
clones equipped to survive the mechanisms used by the immune system, and will 
continue to grow and divide resulting in a continually evolving tumour mass. The tumour 
has been shown to be able to mimic some of the conditions and mechanisms used by the 
natural host response to regulate itself. In doing so it creates immune suppressive 
conditions in the tumour environment which favour growth of the tumour (Dunn et al., 
2002; Dunn et al., 2004). I will describe some of the main mechanisms by which the 
tumour may avoid the immune response below (also see Figure 1.1.). 
 
 18 
 
The barriers faced by the immune system in attacking the tumour come in two forms, the 
passive shielding of the tumour from the immune system and the active suppression of 
the immune system by the tumour and its environment. It has been proposed that the 
nature of tumorigenesis is a slow event resembling chronic infection with a lack of acute 
phase (Zou, 2005). As such, certain elements of the immune system normally involved in 
priming an efficient CD8 T cell response are not activated such as the natural killer cell 
which is known to link the innate and adaptive immune systems (Degli-Esposti and 
Smyth, 2005). This is a passive mechanism of suppressing the host immune response. 
Similarly it has been hypothesised that prior to metastasis of the tumour, it will exist as a 
solid mass. Often the tumour associated antigens (TAA) are hidden within the mass of the 
tumour and inaccessible to the host immune system. Tumours have been shown to 
downregulate MHC class I molecules resulting in a lack of TAA presentation on their 
surface (Restifo et al., 1996). Such methods mask the immune system from antigen 
presented in the correct manner and as such result in a poor, ineffective immune 
response. 
 
The tumour environment itself has a number of soluble factors often produced by cancer 
cells to actively suppress immune cells. Tumours can produce high levels of vascular 
endothelial growth factor (VEGF) which is a potent suppressor of myeloid dendritic cell 
differentiation and maturation (Gabrilovich et al., 1996). Interleukin 6 (IL-6) and 
macrophage colony stimulating factor (M-CSF) have also been shown to be present in the 
tumour environment and switch DC differentiation towards macrophage differentiation 
(Menetrier-Caux et al., 1998). Transforming growth factor (TGF) β and IL-10 are present 
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in high levels which also suppress T cell activity and DC maturation and function (Zou, 
2005). In contrast, cytokines typically associated with a Th1 response are absent or 
present in low levels such as IL-12 and IFNγ (Freedman et al., 2004). As such the tumour 
environment contains an aberrant and suppressive balance of cytokines. 
 
Cell surface markers can also lead to active immunosuppression in the tumour 
microenvironment. Tumour factors present in the environment can lead to upregulation of 
markers such as PD-L1 on DCs, which in combination with the cytokines present, leads 
to DCs incapable of effectively presenting TAAs. PD-L1 will be discussed in detail later, 
although it is worth mentioning here that many tumours have shown PD-L1 expression 
which will contribute to immune suppression (Okazaki and Honjo, 2006). On the other 
hand, markers which may promote T cell stimulation such as CD80 and CD86 are absent 
from DCs in the tumour environment (Khong and Restifo, 2002).  
 
The tumour environment has also been shown to contain high levels of catabolic enzymes 
which can lead to immunosuppression. Reverse signalling on dendritic cells through 
CD80 and CD86 via interactions with cytotoxic T lymphocyte antigen 4 (CTLA-4) cause 
upregulation of indoleamine 2,3 dioxygenase (IDO) (Grohmann et al., 2002). IDO is an 
enzyme that catabolises tryptophan. This not only starves T cell of an essential amino 
acid but produces potent toxic catabolites of the kynurenine pathway (Munn et al., 2002). 
Furthermore certain types of myeloid cell known collectively as myeloid derived 
suppressor cells (MDSC) express inhibitory enzymes such as arginase 1 and nitric oxide 
synthase 2 (NOS-2) (Mazzoni et al., 2002; Rodriguez et al., 2004). Arginase catabolises 
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arginine and has been show to result in downregulation of CD3 on T cells therefore 
preventing their activation (Rodriguez et al., 2004). NOS-2 generates nitric oxide (NO) 
acts on the IL-2 receptor signalling pathway to prevent phophorylation of key molecules 
which induces T cells apoptosis (Mazzoni et al., 2002). 
 
Overall the inhibitory environment of the tumour can directly suppress T cells or prevent 
maturation of antigen presenting cells such as DCs into phenotypes which can stimulate 
an appropriate and effective immune response. Instead of Th1 skewed populations of 
CD4 T cell capable of activating CD8 T cells, often the result is regulatory T cells which 
can add to the suppressive environment and continue to prevent an efficient immune 
response. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Immunosuppression in the tumour 
microenvironment. 1) Downregulation of MHC 
molecules leads to lack of recognition and activation of 
anti-tumour T cells. 2) Upregulation of inhibitory co-
stimulation molecules e.g. PD-L1 on the tumour can 
directly suppress anti-tumour T cell responses. 3) 
Immunosuppressive cytokines such as IL-10 and TGF-β 
can be released by tumour cells and influence the 
phenotype of APCs which then leads to upregulation of 
immunosuppressive molecules such as IDO and arginase 
(4) which can metabolise essential amino acids and 
produce toxic catabolites leading to T cell apoptosis 
and/or anergy. Cell surface inhibitory molecules such as 
PD-L1 can also be upregulated on tumour associated 
APCs which suppress T cells responses. 5) regulatory T 
cells can be recruited to the tumour microenvironment 
which suppress effector T cells 
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1.4. Ovarian Cancer 
Ovarian cancer is the sixth most common cancer worldwide. It is highest among white 
women and lowest among Native American populations (Hankinson et al., 1995). The 
incidence of ovarian cancer is increased after reaching menopause age. Family history 
is thought to be one of the strongest associated risk factors, BRCA1 and 2 mutations 
have been linked with increased incidence of hereditary ovarian cancer (Lynch et al., 
1998). Environmental factors such as nulliparity, fertility drugs and endocrine 
disorders also contribute to risk (Holschneider and Berek, 2000). Increased ovulatory 
events correlate with increased risk possibly due to increased cell proliferation and 
mutation rates. 
 
Malignancies derived from the epithelium of the ovary represent 90% of ovarian 
cancer cases, with the other 10% originating from germ cells, stroma or granulosa 
cells (Friedlander, 1998). Epithelial ovarian cancer (EOC) is the leading cause of 
death among gynaecological malignancies with 5 year survival rates of 30-40% (du 
Bois et al., 2003; Jemal et al., 2005; Ozols et al., 2003). EOC can be further 
subdivided in to histological subtype, these include serous (originating from the 
fallopian tube epithelium); endometrioid (endometrial epithelium); mucinous (endo 
cervix or colonic epithelium), clear cell (gestational endometrial epithelium); and 
transitional (urogenital tract epithelium). 
 
EOC is typically diagnosed in advanced stages (explaining the poor 5 year survival 
rates) and is clinically characterised by periods of remission and relapse of shortening 
duration until chemo-resistance develops (Markman et al., 2004). 60-70% of cases 
will recur in spite of surgical cytoreduction and platinum-paclitaxel chemotherapy (du 
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Bois et al., 2003; Ozols et al., 2003). Established prognostic factors of EOC include 
stage, histologic subtype, grade and volume post surgery. Nevertheless, most cases 
are diagnosed at advanced stages with tumours of high grade so the value of these 
prognostic markers is limited (Holschneider and Berek, 2000; Ozols, 2000). Currently 
the best known tumour marker for ovarian cancer is CA-125. CA-125 is expressed by 
amniotic and coelomic epithelium during foetal development. In the adult, CA-125 is 
expressed by structures derived from the coelomic epithelium, including the 
mesothelial cells of the pleura, pericardium, and peritoneum, and by the tubal, 
endometrial, and endocervical epithelium (Bischof, 1993). A level of CA-125 at 
around 35 U/ml is the upper limit for normal healthy premenopausal females (Canney 
et al., 1984). 85% of patients with ovarian cancer have CA-125 values >35 U/ml 
(Chauhan et al., 2006). Of early stage patients, only 50% have increased CA-125 
compared with 90% of advanced stage patients. This means that CA-125 is not a good 
candidate for early screening of EOC (Nossov et al., 2008). As a further drawback, 
CA-125 is often not commonly elevated in mucinous, clear-cell, and borderline 
tumors  
 
Recently it has been proposed that the presence of tumour infiltrating lymphocytes 
(TILs) is a better prognostic marker than previous ones. Data has indicated that there 
are significant differences in the distribution of progression free survival and overall 
survival according to the presence or absence of intratumoral T cells (Zhang et al., 
2003). The 5 year survival rate is 38% vs. 4.5% in the presence vs. absence of TILs. 
Sato et al. have found that high intraepithelial CD8 T cells leads to improved survival, 
and that the presence of CD4 T cells reduced the benefit of CD8 T cells which they 
suggested was due to populations of CD4
+
 CD25
+
 FoxP3 Tregs (Sato et al., 2005).  
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1.5. Ovarian Cancer Therapy 
The evidence suggesting immune infiltration of EOC may be beneficial to survival 
rates opens the possibility of immunotherapy as a treatment. Primary treatment of 
EOC consists of surgical intervention which facilitates staging and histopathological 
classification of the disease. This is often followed by systemic chemotherapy (Bast et 
al., 1998). Early stage ovarian cancer is often sensitive to platinum based 
chemotherapy. Advanced stages (stage IIIB-IV) are often treated using a combination 
of cisplatin or carboplatin and a taxane (Harries and Gore, 2002a, b). Taxanes, such as 
paclitaxel and docetaxel bind to tubulin polymers whereas platinum analogues 
(cisplatin and carboplatin) form crosslinks with DNA strands (Bookman et al., 1996). 
Although as previously mentioned EOC is characterised by a sequence of remission 
and relapse until chemo resistance develops. As a result there is a lot of work 
currently being trialled in terms of immunotherapies for treatment of EOC.  
 
One example of a peptide based vaccine currently in clinical trials is that of an EOC 
specific TAA known as NY-ESO-1. RT-PCR and immunhistochemical analysis have 
shown that 43% of ovarian tumours express NY-ESO-1. A phase I study used a 
peptide derived from NY-ESO-1 to immunise 18 ovarian cancer patients. A high 
proportion of patients showed NY-ESO-1 specific antibody responses as well as 
CD4+ and CD8+ T cell antigen specific responses. Furthermore long lived and 
functional vaccine elicited CD8+ and CD4+ T cells were detectable in patients up to 
12 months after immunisation. It is important that the vaccine can generate a cellular 
and humoral response against the TAA, which has been shown in this trial (Odunsi et 
al., 2007). However there are still inherent problems with peptide based vaccines 
which include their lack of immunogenicity and biodegradability. Also analog 
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peptides, those produced synthetically rather than through endogenous processing of 
the full length protein, may be antagonistic and stimulate inappropriate immune 
responses (Celis, 2002).  
 
A way around these problems would be to use recombinant full length TAA. A phase 
II trial involving recombinant full length NY-ESO-1 has been carried out. This 
vaccine has been shown to produce a broad immune response against a range of HLA 
class I and II epitopes. The trial involved 19 patients which had resected NY-ESO-1 
positive tumours. High antibody titers, delayed type hypersensitive responses and 
CD4+/CD8+ T cells specific to a wide range of NY-ESO-1 epitopes have been seen 
when using this full length vaccine (Odunsi et al., 2007). 
 
An antibody therapy against ovarian cancer is currently being trialled, known as 
Oregovomab. This antibody is specific for circulating CA-125 (Noujaim et al., 2001). 
The antibody-CA-125 complex is processed by antigen presenting cells and presented 
to T cells. CA-125 specific antibody responses as well as helper T cell and CTL 
responses have been observed (Berek et al., 2003; Noujaim et al., 2001). Phase II 
trials have associated a longer overall survival with an immune response as a result of 
Oregovomab therapy (Ehlen et al., 2005). 
 
A dendritic cell based vaccine specific to ovarian cancer has been reported. Hernando 
et al. have harvested DCs and pulsed with tumour cell lysate in combination with 
GM-CSF using 8 ovarian cancer patients. Significant tumour antigen specific 
responses were seen in 2 patients and progression free intervals of 25-45 weeks have 
been observed in 3 (including the aforementioned 2) (Hernando et al., 2003).  
 26 
 
Finally, adoptive therapy approaches where tumour specific T cells are transferred 
into patients are in early stages for ovarian cancer. Those which have progressed 
further have failed to initiate an effective immune response (Kershaw et al., 2006). 
 
There is clearly a growing trend towards immunotherapeutic options for ovarian 
cancer therapy, however at the moment they are either in early stages or showing a 
lack of efficacy. It is therefore important to continue to search for other targets in 
order to increase the likelihood of finding an efficacious therapy. 
 
1.6. T cell activation 
The two signal model of T cell activation was proposed more than 35 years ago and 
has greatly enhanced our understanding of the mechanisms behind self non-self 
discrimination. It states that T cells require two signals for full activation, which are 
distinct but synergise with each other (Bretscher and Cohn, 1970; Janeway and 
Bottomly, 1994). Signal one is the interaction between the T cell receptor (TCR) and 
an MHC/peptide complex. The co-receptor molecules CD8 and CD4 are also involved 
in this interaction and interact with MHC class I and II respectively. Signals are 
received through the TCR and transduced through the CD3 complex resulting in 
activation of multiple intracellular signalling cascades. Signal two (co-stimulation) is 
the interaction of T cell surface molecules with their ligand/receptors on the surface of 
the antigen presenting cell (APC). Signal one in the absence of signal two results in 
apoptosis of the T cell or the induction of a long-lasting state of partial or total 
unresponsiveness, termed anergy (Schwartz, 1990). Signal two can enable the T cell 
to achieve full activation; however this is not the only outcome, as multiple negative 
co-stimulation signals have been reported. These are thought to be important in 
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maintaining tolerance and homeostatic control over the T cell, and as a result, the B 
cell compartments (Van Parijs and Abbas, 1998). 
 
1.7. Co-stimulation Pathways 
A growing number of molecules are now implicated in controlling the T cell response 
(see Figure 1.2.). There are two families of co-stimulatory molecules; these are the B7 
(e.g. CD28/B7.1 &B7.2) and Tumour Necrosis Factor (TNF) (e.g. CD40-CD40L) 
superfamilies (Croft, 2003). All co-stimulation molecules have differing expression 
patterns in terms of where and when they are expressed; they also mediate different 
effects on the cells involved which overall adds a large amount of control to the T cell 
response and therefore the resulting immune response. 
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Figure 1.2. B7 family member molecules. Interactions between the T cell and antigen presenting cell 
involve the engagement of the MHC molecules on the APC with the T cell receptor (TCR). B7 family 
members provide the second signal to activate or inhibit T cell responses. CD28 and CTLA-4 on the T cell 
both interact with CD80 and CD86 on the APC to deliver opposing signals. CD28 activates T cells whereas 
CTLA-4 inhibits T cells. These signals are provided early in the activation of T cells. More recently 
discovered members of the B7 family are involved in later stages and include the ICOS-ICOSL interaction 
which maintains T cell activity. PD-1 Interacting with its ligands PD-L1 and PD-L2, sends an inhibitory 
signal to the T cell. Recently the interaction between PD-L1 and CD80 has been described to be inhibitory 
to the T cell. Finally a new member of the B7 family has been identified, B7-H4, and has been shown to be 
inhibitory to the T cell when interacting with its unknown ligand. The balance of the signals determines the 
overall activation of the T cell and the tumour environment has been shown to have an imbalance of B7 
molecules expression which may lead to inhibition of anti-tumour immune responses. ICOS: inducible co-
stimulator; PD-1: programmed cell death-1; CTLA-4: cytotoxic T-lymphocyte antigen 4 
APC T cell 
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1.7.1. CD28 Pathway 
The best characterised co-stimulatory pathway is that of the CD28/CTLA-4 – B7 
pathway. CD28 is expressed on primed and naïve T cells and can bind the B7 family 
members B7.1/CD80 and B7.2/CD86 expressed on professional APCs (Coyle and 
Gutierrez-Ramos, 2001). Both ligands have similar functions however their 
expression pattern differs in terms of timing. CD86 is constitutively expressed on 
APCs and its levels are upregulated rapidly. CD80 on the other hand, is expressed in 
low levels on resting APCs and is upregulated after interaction with T cells (Kim et 
al., 2001; McAdam et al., 1998).  
 
The interaction of CD28 with CD80 and CD86 results in T cell activation, clonal 
expansion, cytokine secretion, T cell survival and the ability to provide help to B cells 
(Yamada et al., 2002). CD28 signalling has been shown to decrease the threshold 
required for T cell activation, by significantly reducing the number of TCR 
engagements necessary to achieve T cell activation (Viola and Lanzavecchia, 1996). 
It has been stated that CD28 signalling augments the production of IL-2 by 30-100 
fold and also maintains IL-2 mRNA levels at later timepoints following the initial 
increase (Umlauf et al., 1995). 
 
Cytotoxic T lymphocyte antigen 4 (CTLA-4 or CD152) shows ~30% homology to 
CD28 and is rapidly upregulated following T cell activation (Linsley and Golstein, 
1996). Like CD28 it binds CD80 and CD86, albeit with a much higher affinity (10-20 
fold higher). This is due to an avidity advantage of the bivalent CTLA-4 over the 
monovalent CD28. It therefore acts a negative regulator of T cell activation by out 
competing CD28 for the B7 molecules. CTLA-4 also negatively regulates T cell 
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activation by recruitment of the phosphatases, SH2 domain containing protein 
tyrosine phosphatase 2 (SHP-2) and PP2A which can inactivate downstream TCR 
signalling (Marengere et al., 1996). Specifically CTLA-4 signalling has been shown 
to inhibit transcription factors NF-κB, nuclear factor of activated T cells (NFAT) and 
activator protein-1 (AP-1) (Fraser et al., 1999). The importance of CTLA-4 in the 
maintenance of peripheral tolerance is illustrated by the observation that CTLA-4 
deficient mice exhibit extensive lymphoproliferative disorders and multi-organ 
autoimmune disease (Waterhouse et al., 1995). CTLA-4 is also an important molecule 
employed by the CD4
+
 CD25
+
 subsets of regulatory T cells (Tregs) (Takahashi et al., 
2000). There is evidence to suggest that reverse signalling through CD80 and CD86 
on APCs via CTLA-4 engagement can lead to upregulation of IDO, which can lead to 
T cell anergy and apoptosis.  
 
Although CD80 and CD86 bind both CTLA-4 and CD28, they have non-equivalent 
roles in immune modulation. The CD80-CTLA-4 interaction is of much higher 
affinity than the CD86-CTLA-4 interaction. CD28 binds CD86 with higher affinity 
then it binds CD80 (Collins et al., 2002). The CD80 interaction with CTLA-4 results 
in a cross-linked lattice following CD80 dimerisation. CD86 on the other hand has 
been shown to remain in a monomeric form unlike the dimeric CD80, and results in a 
monovalent interaction with CD28 (Stamper et al., 2001). The models describing the 
selective interaction of CD80 with CTLA-4 and CD86 with CD28 will likely result in 
functional differences between CD80 and CD86. The stabilisation of CD28 and 
CTLA-4 at the immunological synapse has been shown to be dependent on the 
presence of the preferred ligand in both cases (Pentcheva-Hoang et al., 2004). 
Similarly blocking antibodies against CD86 in animal models of autoimmunity 
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ameliorated the disease whereas blocking antibodies against CD80 have shown to be 
ineffective (Nakajima et al., 1995; Peterson et al., 1999). This suggests that CD80 and 
CD86 may have distinct differences in function. However a study showing that CD80 
KO mice do not suffer from the same lymphoproliferative disorder that affects CTLA-
4 KO mice suggests that these preferences are not absolute and the CD86-CTLA-4 
interaction is sufficient to prevent lymphoproliferation (Borriello et al., 1997). 
 
1.7.2. Programmed Cell Death-1 (PD-1) 
PD-1 was initially discovered as a gene upregulated in a T cell hybridoma undergoing 
cell death (Ishida et al., 1992). The PD-1 (CD279) molecule is upregulated following 
activation of the T cell, and like CTLA-4 it initiates an inhibitory signalling pathway, 
when ligated by programmed cell death-ligand 1 (PD-L1, B7-H1, CD274) and PD-L2 
(B7-DC, CD273) (Agata et al., 1996). 
 
PD-1 is a 50-55 kDa type I transmembrane protein with an Ig variable-like 
extracellular domain. It is structurally related to CD28 and CTLA-4 but it lacks the 
cysteine residue responsible for homodimerisation in these molecules. PD-1 lacks the 
MYPPPY motif which is conserved in CD28 and CTLA-4 and is responsible for their 
binding of the CD80/86 molecules. Its cytoplasmic tail contains an immunoreceptor 
tyrosine-based inhibitory motif (ITIM) as well as an immunoreceptor tyrosine-based 
switch motif (ITISM) suggesting an association with the inhibitory phosphatases 
SHP1 and 2 (Latchman et al., 2001; Shinohara et al., 1994). 
 
PD-1 exhibits a broad expression pattern and is expressed by T, B and myeloid cells 
as well as a subset of thymocytes (Agata et al., 1996). PD-1 is not constitutively 
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expressed on lymphocytes and requires ligation of the TCR or B cell receptor (BCR) 
before upregulation, which is detectable after 24 hours although functional effects 
may be seen after a few hours (Chemnitz et al., 2004). 
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Figure 1.3. Structure of PD-1. Part A 
shows the structure and positioning of 
human PD-1 on the cell surface 
interacting with its ligand PD-L2. The 
structure of PD-1 shows a single IgV 
domain which interacts with the IgV 
domain of PD-L2. Part A also shows the 
interaction of the TCR with the MHC 
complex and the CTLA-4 interaction 
with B7.1 demonstrating the contrasting 
nature of the monomeric PD-1/PD-L2 
interaction. Part B shows a 
crystallographic structure of the 
extracellular domain of PD-1 interacting 
with PD-L2. Labelled is the approximate 
location of the cysteine 60 residue which 
is important for chapter 4 of this thesis. 
This diagram is adapted from Lazar-
Molnar et al 2008. 
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1.7.3. Programmed Cell Death Ligand 1 and 2 (PD-L1/2) 
PD-L1 and PD-L2 are both type I transmembrane proteins which consist of an IgV 
and IgC domain. Both are monomeric. PD-L1 has been shown to be expressed at the 
mRNA level on haematopoietic cells as well as various human tissues for example 
vascular endothelial cells, muscle cells and hepatocytes (Dong et al., 2002).  This is in 
contrast to CD80 and CD86 which show a more restricted expression pattern. Despite 
this broad level of transcription of the PD-L1 gene, the protein level is more limited in 
normal tissue but can be induced under inflammatory conditions (Dong et al., 2002). 
Its expression on haematopoietic cells has been shown to be constitutive and can be 
further upregulated during inflammation particularly in response to both type I and II 
interferons (Dong et al., 2002). PD-L1 has been shown to be expressed highly at 
immune privileged sites such as the placenta and the corneal endothelium (Petroff et 
al., 2002; Watson et al., 2006). In contrast, PD-L2 is limited to dendritic cells and 
macrophages, similar to CD80 and CD86 (Greenwald et al., 2005) PD-L2 has been 
shown to be upregulated by IFNγ, GM-CSF and IL-4 (Loke and Allison, 2003; 
Yamazaki et al., 2002). 
 
Binding of the ligands to PD-1 can inhibit T cell by delivering inhibitory signals 
resulting in a decrease in cytokine production and cell cycle arrest (Carter et al., 2002; 
Chemnitz et al., 2004; Freeman et al., 2000; Latchman et al., 2001). It has been shown 
that inhibition delivered through the PD-1 pathway may be dependent on the strength 
of the TCR signal. Lower strength TCR signalling is more susceptible to inhibition 
than higher strength (Freeman et al., 2000). Mechanistically, PD-1 inhibition is 
thought to be mediated through interfering with early activation events regulated by 
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CD28 or IL-2 (Carter et al., 2002). In addition it has been shown that PD-1 signalling 
can lead to inhibition of the anti-apoptotic Bcl-xL (Chemnitz et al., 2004). 
 
Recent evidence has shown that PD-L1 has an additional binding partner (Figure 
1.4.). It has been shown that PD-L1, but not PD-L2, can bind CD80 (Butte et al., 
2007). Surface plasmon resonance studies have shown that the interaction has an 
affinity intermediate between that of CD80 and CD28/CTLA-4 and that of PD-L1 and 
PD-1 (Wang et al., 2003). The exact relevance of this interaction is not yet fully 
known but it has been proposed that this pathway may serve to inhibit T cells. T cells 
express CD80, and it is thought that a reverse signal through CD80, mediated by PD-
L1 delivers an inhibitory signal to the T cell (Butte et al., 2007; Paust et al., 2004; 
Taylor et al., 2004). PD-L1 is also present on the T cell, and so a bidirectional 
signalling pathway can be established between the APC and the T cell. This pathway 
increases the complexity of costimulation pathways and starts to bring together 
pathways which were once considered distinct.  
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Figure 1.4. Crosstalk between the CD28 and PD-1 pathways. CD28 interacts with the CD80 
and CD86 ligands to send a stimulatory signal to the T cell. CTLA-4 interacts with the same 
ligands, CD80 and CD86 to oppose the CD28 signal and inhibit T cells. The PD-1 pathway is 
important in the later stages of the immune response and PD-1 on T cells interacts with PD-L1 and 
PD-L2 on the APC to send an inhibitory signal to the T cell. Recent data shows that the PD-1 
pathway and the CD28 pathway can cross over adding more complexity to the previously defined 
pathways of co-stimulation. PD-L1 is also expressed on T cells and can interact with CD80, but not 
CD86, on the APC. This sends an inhibitory signal to the T cell. This is important in studies 
involving blocking the PD-1 pathway for immunotherapy as there has to be consideration of 
whether to block PD-L1 interacting with PD-1 and CD80 or just the individual interactions alone. 
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1.8. The Role of the PD-1 Pathway in Tolerance 
The first evidence of the role of the PD-1 pathway in the maintenance of immune 
tolerance came with the observation that Pdcd1
-/-
 mice (PD-1 knockout mice) develop 
spontaneous, late onset lupus like disease (Nishimura et al., 1999). Also the same 
single nucleotide polymorphism (SNP) which is linked to these mice is also 
associated with rheumatoid arthritis, type I diabetes mellitus and ankylosing 
spondylitis (Chen, 2004). This phenotype is similar to that of the CTLA-4
-/-
 mouse, 
although the onset of disease is later suggesting that PD-1 plays a later role in the 
inhibition of T cells. The presence of PD-1 in CTLA-4
-/-
 mice does not prevent the 
onset of lymphproliferation suggesting it is not the major inhibitory signal for the T 
cell. I will now break down the role played by the PD-1 pathway in control of 
immune tolerance into central and peripheral tolerance. 
 
1.8.1. Central Tolerance 
The PD-1 pathway takes part in “fate decisions” at several stages of T cell maturation. 
PD-L1 is widely expressed in the thymic cortex, with PD-L2 being expressed on 
medullary stromal cells. PD-1 itself has been shown to be expressed on double 
negative thymocytes (Blank et al., 2003). Signalling through PD-1 is thought to play a 
role in selection of the TCR repertoire by controlling activation thresholds. Overall 
the PD-1 pathway can contribute to both positive and negative selection in the thymus 
(Blank et al., 2003). 
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1.8.2. Peripheral Tolerance 
As mentioned previously, PD-L1 is expressed on a wide range on non-haematopoietic 
tissues. In addition PD-L1 expression has been detected in classical immune 
privileged sites. PD-L1 is expressed highly on placental syncytiotrophoblasts and PD-
L2 is expressed on placental vascular endothelial cells (Blank et al., 2003). Functional 
studies also back up the suggestion that these ligands play a key role in peripheral 
tolerance. Foetal abortion rates increase following administration of anti-PD-L1 
blocking antibody. This is associated with an increase in T cell infiltration into the 
placenta (Guleria et al., 2005). 
 
In addition, PD-L1 is constitutively expressed in the cornea, iris-cilliary body and the 
retina (PD-L2 or PD-1 do not show the same expression pattern) (Watson et al., 
2006). Blocking PD-L1, but not PD-L2, increases allograft rejection and furthermore 
PD-L1-Ig substantially prolongs corneal allograft survival in vivo and almost entirely 
inhibits inflammatory cell infiltration (Watson et al., 2006). 
 
The above functional data clearly shows a role for the PD-1 pathway in the 
maintenance of peripheral tolerance at the effector stage of the immune response. It is 
also important to consider the role played by the PD-1 pathway during the afferent 
arm of the immune response. Dendritic cells (DC) with high expression of PD-L1 and 
myelin antigen presentation ameliorate experimental allergic encephalomyelitis 
(EAE) and stop macrophage and T cell infiltration of the spinal cord (Hirata et al., 
2005).  
 
 39 
 
Soluble PD-1 has also been used to reverse signal to dendritic cells, resulting in a 
downregulation of maturation markers (CD40, CD80, CD86), increasing IL-10 
production and creating a suppressive DC phenotype (Kuipers et al., 2006). 
 
1.9. Mechanism of action of PD-1 pathway 
There have been a number of mechanisms described by which a cell expressing PD-
L1 can evade T cell immunity. The first mechanism is induction of apoptosis. Co-
culture of PD-L1
+
 tumour cell lines increased the apoptosis of human tumour antigen 
specific T cells, blocking PD-L1 decreased this apoptosis (Dong et al., 2002). 
Although it is unclear yet, as to whether PD-L1 can mediate this apoptosis solely 
through its interaction with PD-1 or whether its interaction with CD80 is also 
involved. Experiments in mice and humans suggest there may be a case for 
involvement of both interactions. Whereas PD-L1 can induce apoptosis in human PD-
1
- 
cells, most mouse models require PD-1 for PD-L1 mediated apoptosis (Chen, 2004; 
Dong et al., 2002). 
 
The PD-1 pathway can also induce anergy in T cells. Culture with IL-10 treated DCs 
induced unresponsive T cells similar to anergic T cells, which could be rescued by 
restimulation of DCs treated with anti PD-L1 antibody (Selenko-Gebauer et al., 
2003). 
 
Recently models of chronic infection have shown a role for the PD-1 pathway in 
exhaustion of T cells. PD-1 is expressed on functionally exhausted antigen-specific T 
cells in HIV. Blockade of PD-1 or PD-L1 can rescue the function of these exhausted 
T cells (Barber et al., 2006; Day et al., 2006). Cancer has been considered as a chronic 
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inflammatory disease and PD-L1 has been shown to be expressed on dendritic cells 
associated with cancer and on tumour cells themselves (Coussens and Werb, 2002; 
Curiel et al., 2003). Furthermore, PD-1 has been shown to be expressed on tumour 
infiltrating T cells in patients with melanoma and that the blockade of this PD-1 
increased T cell proliferation (Wong et al., 2007). Taken together these results suggest 
the PD-1 pathway may contribute to T cell suppression in cancer via exhaustion of 
antigen specific T cells similar to that observed in chronic infection. 
 
It has also been suggested that PD-L1 is involved in the development and function of 
regulatory T cells (Tregs). PD-L1+ vascular endothelial cells and gastric epithelial 
cells have been shown to induce the development of Tregs in an in vitro culture 
system (Beswick et al., 2007; Krupnick et al., 2005). Treg function has also been 
shown to be abrogated by blockade of PD-L1 with an antibody (Sharma et al., 2007). 
Although in contrast to this, intratumoral Tregs in non-Hodgkins lymphoma have 
been shown to express PD-L1 and blocking with an anti-PD-L1 antibody partially 
decreased Treg mediated T cell inhibition (Yang et al., 2006). Therefore the exact role 
of the PD-1 pathway in Treg function remains to be determined; however there is 
some evidence to suggest that Tregs may be another PD-L1 influenced mechanism 
resulting in suppression of Tcells. 
 
1.10. Studies Involving Blockade of the PD-1 Pathway in Tumour 
Immunotherapy 
Research into immunotherapies has been intensified over the last ten years as an 
alternative to conventional cancer therapies. In particular, research into targeting of 
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costimulation pathways has been carried out to try and enhance T cell responses 
against tumours (Abbott, 2002). 
 
The PD-1 pathway members are commonly found amongst the numerous soluble and 
cell surface expressed markers found in the inhibitory microenvironment. Many 
human and mouse tumours have been shown to express PD-L1 (Okazaki and Honjo, 
2006).  Tumour cell lines express this ligand constitutively or can be induced to do so 
in response to IFNγ. In addition the level of PD-1 expression on tumour infiltrating 
lymphocytes (TIL) has been shown to be higher than that of their peripheral 
counterparts (Okazaki and Honjo, 2006). Sections of tissues from clear cell renal 
carcinoma stained with anti-PD-L1 antibody showed that PD-L1 expression is an 
indicator of poor prognosis for patient survival (Thompson et al., 2004). Similarly 
PD-L1 expression has been identified as a poor prognosis factor in oesophageal and 
gastric carcinomas (Ohigashi et al., 2005; Wu et al., 2006). Overall this suggests some 
significant role of the PD-1 pathway in the promotion of tumour growth and 
functional studies have strengthened this suggestion. 
 
PD-1
-/-
 mice have increased resistance to tumour engraftment, this is coupled with an 
increases in cytokine production and T cell infiltration into the tumour (Iwai et al., 
2002). In 2002 Dong et al. carried out experiments using the mastocytoma line P815 
to further investigate the role of the PD-1 pathway in tumour survival. Expression of 
PD-L1 in B7.1
+
 P815 cells resulted in increased growth and progression of these 
tumour cells. The authors suggested this demonstrated that even in the presence of 
strong CD28 costimulation, the PD-L1 expression is enough to overcome and evade 
tumour immunity. Furthermore, transplantation of PD-L1
+ 
P815 tumours into RAG
-/-
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mice, followed by injection of P815 antigen specific T cells still showed tumour 
evasion and apoptosis of the tumour specific T cells. This effect was reversed upon 
addition of anti-PD-L1 antibody (Dong et al., 2002). 
 
In vitro human experiments have also suggested an important role for the PD-1 
pathway in tumour evasion. Activity of TAA specific T helper and CTLs by 
stimulating with TAA pulsed DCs was enhanced in the presence of anti PD-L1 
antibody (Blank et al., 2006). This blockade of the PD-1 pathway led to an increase in 
cytokine production, and increased cytolytic activity of tumour specific CTLs (Blank 
et al., 2006). Aside from studies enhancing a tumour specific response by blocking the 
PD-1 pathway, a number of human in vitro studies have shown that blockade of the 
PD-1 pathway will enhance T cell responses (Blank et al., 2003; Rodig et al., 2003). 
These experiments can be used as a basis for investigating the importance of the PD-1 
pathway in enhancing tumour specific responses within different T cell subsets. 
 
1.11. PD-1 Pathway in Ovarian Cancer 
Recent developments in surgery and chemotherapeutic regimens have prolonged the 
short term survival of ovarian cancer patients. However, the long term prognosis in 
those patients with advanced stages of the disease is still unsatisfactory (Jemal et al., 
2005; McGuire et al., 1996). As mentioned previously, newer prognostic markers are 
being used such as the presence of tumour infiltrating lymphocytes which have shown 
to correlate with prognosis in such cancers such as melanoma, colorectal, oesophageal 
as well as ovarian (Clemente et al., 1996; Jass, 1986; Naito et al., 1998; Nakano et al., 
2001; Schumacher et al., 2001). At present, there are few reports which have used a 
specific molecule to gauge the extent of the host immune response to the cancer. 
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Very few studies have looked at the role of the PD-1 pathway in ovarian cancer. 
Below is a summary of the work that has been carried out on the role of the PD-1 
pathway in ovarian cancer. Currently this consists of 4 papers documenting the 
expression of PD-1 and its ligands in human ovarian cancer, one functional study in 
human ovarian cancer and two murine studies. The lack of previous work on the 
pathway in this cancer gives a good basis for the aims set out in this thesis. 
 
PD-1 ligands have been found to be upregulated on a variety of different malignancies 
including oesophageal, kidney, lung and brain tumours (Dong et al., 2002; Konishi et 
al., 2004; Strome et al., 2003; Thompson et al., 2004; Wintterle et al., 2003). In some 
cases, expression of PD-1 ligands correlates with prognosis. One important study has 
been carried out by Hamanishi et al, and looked at the expression of PD-L1 and PD-
L2 on paraffin embedded sections of ovarian tumours of differing grades. The authors 
found that overall survival of patients with low expression of both markers was 
significantly better than those patients with both or just one of the two ligands (5yr 
survival rate low expression vs. high expression of both ligands = 86.2% vs. 43.2%). 
Furthermore this study relates PD-L1 to a known prognostic marker of ovarian 
cancer, intraepithelial CD8
+
 T cells. The results show and inverse correlation between 
PD-L1 expression and CD8 count (Hamanishi et al., 2007). 
 
This paper states that PD-L1 can be used as an independent prognostic marker in 
ovarian cancer, similar to findings in renal and gastric cancer studies, although in 
contrast to lung cancer where the ligand cannot be used to correlate prognosis 
(Hamanishi et al., 2007).  
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Another study involving PD-1 and ovarian cancer shows a functional relationship 
between PD-L1 on antigen presenting cells and suppression of anti tumour T cell 
responses in a mouse model of ovarian cancer. Liu et al have shown a group of cells 
known as myeloid derived suppressor cells (MDSC) (CD11b
+
 Gr1
+
) have high levels 
of PD-L1 expression if isolated from a mouse bearing ovarian cancer. MDSCs from 
naïve mice did not have detectable PD-L1, although culturing in the presence of the 
1D8 ovarian cancer cell line could induce PD-L1 on these MDSCs. The authors show 
a relationship between PD-L1 expression on MDSCs in the presence of ovarian 
cancer and a functional relevance on the immune response against the cancer. siRNA 
knockdown of PD-L1 alleviated suppression of anti tumour immune responses 
mediated by CD4
+
 FoxP3
+
 Tregs, which the authors suggest require PD-L1 
engagement of PD-1 on their surface to function (Liu et al., 2008). 
 
The authors of this paper continued the theme of PD-1 pathway signalling of MDSCs 
in ovarian cancer leading to suppression of anti tumour immune responses by 
exploring the role of PD-1 on MDSCs on arginase production. Arginase is an enzyme 
which breaks down arginine into urea which has been shown to inhibit T cell activity 
due to down regulation of the CD3 complex. The paper shows that blockade of PD-1 
and PD-L1 on MDSCs leads to a downregulation of arginase activity and an increase 
in in vitro T cell responses. Blockade of PD-1 and CTLA-4 on the MDSCs was also 
shown to significantly slow 1D8 tumour growth in the mouse model (Liu et al., 2009). 
 
Curiel et al. showed the effect of the tumour environment on PD-L1 expression on 
myeloid dendritic cells (MDCs). They showed that MDCs generated from the lymph 
nodes or blood of controls had significantly lower PD-L1 than those generated from 
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lymph nodes and ascites of ovarian cancer patients. This was investigated further and 
it was shown that culturing the MDC precursors with tumour macrophages, which 
produce IL-10 and VEGF, leads to PD-L1 expression which can be reduced using 
blocking antibodies against IL-10 and VEGF. Functionally, the presence of IL-10 or 
tumour macrophages during MDC differentiation meant that the MDCs generated 
poorly stimulated T cells in an MLR, an effect which was reversed on addition of a 
PD-L1 blocking antibody. To show the effect in vivo, T cells were first activated in 
vitro with tumour pulsed MDCs generated from ovarian cancer ascites with or without 
the presence of PD-L1 blocking antibody. The T cells were then transferred into 
tumour bearing mice and it was demonstrated that those T cells which were activated 
by tumour pulsed MDC in the presence of PD-L1 blocking antibody could 
significantly slow the progression of tumours in the mice compared to those T cell 
which were activated in the absence of anti-PD-L1 antibody (Curiel et al., 2003). 
 
The results described above represent what is known about the PD-1 pathway in 
ovarian cancer at the time of writing. There is evidence to suggest that PD-L1 can be 
used as a prognostic marker and that the pathway may be important in the suppression 
of T cell responses, either directly via dendritic cell PD-L1 engagement of PD-1 on 
effector T cells or indirectly through MDSC PD-1 pathway controlled release of 
arginase and activity of Tregs. Overall these data suggest that exploring the role of 
PD-1 in ovarian cancer could lead to potential targets for effective therapy. 
 
1.12. KDEL Fusion Protein Technology  
Proteins are produced in the endoplasmic reticulum (ER) which is the first step along 
the intracellular secretory pathway. The ER contains a number of soluble and 
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membrane bound proteins which can act as chaperones to aid in the folding, 
modification and maturation of newly synthesised proteins (Vitale and Denecke, 
1999). These chaperones, such as calreticulin and calnexin, contain ER retention 
sequences KDEL/HDEL at their C termini which can bind the KDEL receptor 
expressed in both the ER and Golgi and aid retention or retrieval of KDEL fused 
proteins to the ER (Munro and Pelham, 1987; Pelham, 1989). The receptor, ERD2, 
transports KDEL fused proteins via COP I coated transport intermediates (Orci et al., 
1997). The fused protein is thought to be released in the ER due to changes in pH 
(Cabrera et al., 2003; Wilson et al., 1993). 
 
The KDEL sequence has been exploited as a means of down regulating expression of 
cell surface markers (Figure 1.4.). Tan et al. used CTLA-4 fused to KDEL to 
downregulate the level of CD80 and CD86 on the surface of human dendritic cells. 
The theory is that CTLA-4 KDEL is transfected into cells where it is expressed and 
retained in the ER. Here it can bind its ligands CD80/86 and prevent their transport to 
the cell surface. The retained proteins can be degraded by ubiquitin mediated lysis by 
the proteosome (Tan et al., 2005). 
 
Tan et al. went on to show that in a human in vitro system, CLTA4 KDEL inhibits 
DC expression of CD80/86 without affecting other markers. This was later confirmed 
in a mouse in vivo model in Professor George’s laboratory (Dr. Adnan Khan, 
unpublished). The KDEL technology offers an advantage over antibody blockade or 
siRNA mediated knockdown of ligands as one construct can be used to knock down 
multiple ligands. This is preferential in cases where a receptor has more than one 
ligand such as CTLA-4 or in the case of this study, PD-1. Transfection of mammalian 
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cells is often a difficult procedure so the use of one single KDEL construct is 
advantageous over transfecting multiple siRNA contructs. Furthermore the blocking 
of the ligands can be restricted to a particular cell type, unlike with antibodies which 
have no restriction of cell type and cause a generic blockade. 
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Figure 1.5. Mechanism of action of PD-1 KDEL fusion protein. 1) Following transfection of the 
target cell with PD-1 KDEL construct is transcribed and the message is translated in the rough 
endoplasmic reticulum where the protein is folded. 2) PD-1 KDEL fusion protein interacts with newly 
synthesised PD-L1 and 2 present in the ER. 3) The PD-1 KDEL/PD-L1/2 complex binds the ERD 2 
receptor via the KDEL signalling tag. The complex is retained in the ER and therefore the PD-1 ligands 
cannot be transported to the surface and there is a reduced level of PD-L1 and 2 on the cell membrane. 
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1.13. Aims 
Overall, it is clear that the tumour microenvironment has evolved in a way to actively 
suppress the immune response. Very little work has been done on the PD-1 pathway 
in human ovarian cancer, although the data which is available suggests that PD-L1 
could be used as a prognostic marker and that the PD-1 pathway would be a 
potentially beneficial target in ovarian cancer immunotherapy. Through collaboration 
with Dr. Sadaf Ghaem-Maghami (Imperial College London), we have regular access 
to blood and ascites from recently diagnosed ovarian cancer patients of differing 
stage, grade and histological subtype. Furthermore, these patients are all pre 
chemotherapy and represent a chance to extensively study the tumour environment 
including the tumour mass, immune system and soluble factors in the surrounding 
ascites. PD-L1 expression on ovarian cancer has so far been restricted to paraffin 
embedded sections of the tumour, or extraction and in vitro manipulation of the 
myeloid cells associated with the tumour. We proposed to investigate the expression 
of PD-1 and its ligands on freshly isolated immune cells and apply these findings to 
test their functional relevance. As an extension to the project, a novel PD-1 KDEL 
construct will be used to manipulate PD-1 ligand expression during in vitro 
experiments. 
 
Specific Aims: Part 1 
 
1. Fully phenotype the immune cells present in ovarian cancer patient ascites and blood 
for PD-1 and PD-1 ligand expression 
2. Analyse tumour cell mass for PD-1, PD-1 ligands and infiltrating immune cells 
3. Analyse the cytokine content of the ascites from patients with ovarian cancer 
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4. Use any findings in functional experiments to evaluate their biological relevance to 
ovarian cancer 
 
Specific Aims: Part 2 
 
1. Create a PD-1 KDEL fusion protein and demonstrate its function in PD-1 ligand 
expressing cells 
2. Use the construct in functional experiments to demonstrate the potential use of PD-1 
ligands as a target for ovarian cancer therapy. 
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2. MATERIALS AND METHODS 
 
2.1. Buffers and Solutions 
Solution Recipe 
PBS 8g NaCl, 0.2g KCl, 1.44g Na2HPO4, 
0.24g KH2PO4 
PBS Tween PBS, 0.1% v/v Tween 20 
Blocking Solution (Western Blot) PBS, 5% w/v milk powder, 0.1% v/v 
Tween 20 
Running Buffer 12.5 mM Tris Base, 142 mM Glycine, 
0.1% w/v SDS 
Transfer Buffer 12.5 mM Tris Base, 142 mM Glycine, 
20% v/v methanol 
FACS buffer 3% v/v Sterile filtered FCS in PBS  
MACS buffer PBS, 0.5% FCS v/v, 2 mM EDTA 
Red Cell Lysis Buffer 8.3g NH4Cl, 1.0g KHCO3, 1.8ml of 5% 
w/v EDTA  
 
Table 1: Buffers and Solutions used in this project. All chemicals sourced from 
Sigma except FCS from PAA. Abbreviations: PBS; Phosphate Buffered Saline, BSA; 
Bovine Serum Albumin, SDS; Sodium Dodecyl Sulphate, FCS; Foetal Calf Serum 
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2.2. Cell Culture 
2.2.1. Cell Culture Methods 
All cells were cultured in a humid environment at 37
o
C with 5% CO2.  Adherent cells 
(e.g. CHO) were passaged by trypsinisation (Trypsin (0.05% Trypsin, 0.53 mM 
EDTA) (Invitrogen, Paisley, UK).  Suspension cells (Primary cells and THP-1) were 
passaged by diluting 1:2 with fresh medium. All cell culture was carried out in a 
sterile class II cabinet. 
 
2.2.2. Culture Media 
Culture media was supplemented with foetal calf serum (FCS) (PAA Laboratories, 
Somerset, UK), penicillin/streptomycin sulphate (stock 5000U/ml each) (Lonza, 
Wokingham, UK) or L-glutamine (stock 200mM) (Cambrex, Wokingham UK) 
depending on the cell type. 
 
Name Description Company 
R10 RPMI 1640 +10% v/v FCS +2% v/v 
Pen/Strep  +1% v/v  L-Glutamine 
Invitrogen  
D10 DMEM 1640 +10% v/v FCS +2% v/v 
Pen/Strep 
Invitrogen  
Optimem Optimem +2% v/v Pen/Strep Invitrogen  
 
Table 2: Cell Culture Media used in this project 
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2.2.3. Cell Lines 
Cell lines were obtained from American Tissue Culture Collection (ATCC) or 
European Collection of Cell Cultures (ECACC). All human epithelial ovarian cancer 
cell lines were provided by the laboratory of Dr. Sadaf Ghaem-Maghami (Imperial 
College London). 
 
Name Origin Culture 
Medium 
HEK 293 Human Embryonic Kidney cell line D10 
D17 Canine Osteosarcoma cell line D10 
HCEC Human Corneal Endothelial Cells R10 
OVCAR-3 Human Epithelial Ovarian Cancer (EOC) cell line, 
serous histology 
R10 
OVCAR-5 Human EOC cell line, serous histology R10 
CaOV Human EOC cell line, serous histology R10 
SKOV-3 Human EOC cell line, serous histology R10 
IGROV-1 Human EOC cell line, serous histology R10 
OVISE Human EOC cell line, clear cell histology R10 
TOV21G Human EOC cell line, clear cell histology R10 
SMOV Human EOC cell line, clear cell histology R10 
 
Table 3. Cell Lines used in this Project. Abbreviations: EOC; epithelial ovarian 
cancer 
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2.2.4. Primary Cell Culture 
Primary cells were separated from human blood or ascites samples from ovarian 
cancer patients. Ascites was provided by the laboratory of Dr. Sadaf Ghaem-Maghami 
(Imperial College London). Patients’ blood and ascites was collected over a 2 year 
period and were classified as either having malignant or benign/borderline ovarian 
cancer. Of those patients with malignant ovarian cancer, 90% of cases were of serous 
histology and the remaining 10% were clear cell. Each of the patients gave consent 
for the use of ascites and/or blood to be used in this study and ethical approval for this 
study was obtained prior to collection of samples. Patients were assigned a three digit 
code which is used in this thesis e.g. patient number 291. See method 2.2.5. for details 
of isolation of cell types. 
 
Name Culture Conditions 
Human T cells Cultured in R10 supplemented with CD3/CD28 beads 
and PHA (see method 2.2.7.) for activation or in R10 to 
be mixed with a stimulator cell population in a mixed 
lymphocyte reaction (MLR) 
Human Monocytes Cultured in R10 media to be used in an MLR. For 
differentiation to dendritic cells see below. 
Human Dendritic Cells Human monocytes cultured in R10 supplemented with 10 
ng/ml of IL-4 and GM-CSF for 6 days. 
 
Table 4: Primary Cells used in this Project. Abbreviations: PHA; 
Phytohaemaglutinin, IL-4; Interleukin-4, GM-CSF; Granulocyte Macrophage-Colony 
Stimulating Factor 
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2.2.5. Isolation of Human Peripheral Blood and Ascitic Mononuclear Cells 
 
Blood (from a buffy coat (NHS, Colindale, UK) or patient) and ascites were layered 
over Lymphoprep/Ficoll (Axis Shield, Cambridge, UK) in a 3:1 ratio (blood is first 
diluted with PBS in a 1:3 ratio, ascites samples are not diluted) and centrifuged at 800 
x g for 20 minutes at room temperature with low brake. The mononuclear cells form a 
white layer which is removed using a pipette and transferred into a clean tube. Cells 
are washed in PBS and then cultured in media or further separated as described later 
(2.2.6. and 2.2.8.). Any red blood cell contaminants were removed by re-suspending 
the pelleted cells in red cell lysis buffer for 10 minutes at room temperature; lysed 
cells were then removed by washing in PBS. 
 
2.2.6. Isolation of T cells From Human Peripheral Blood (PBMCs) and Ascitic 
Mononuclear Cells (AMCs) 
 
T cells were isolated  using a negative selection technique. Mouse anti-human CD14, 
CD16, CD19 and CD56 antibodies (all Chemicon, Watford UK) along with CD33 
beads (BD Bioscience, Oxford UK) were added to 1 ml of R10 at a concentration of 
0.1 μg/ml. PBMCs and AMCs were centrifuged at 800 x g for 5 minutes and the pellet 
was resuspended in the 1 ml of media containing the antibodies. This mixture was 
then incubated for 30 minutes at 4
o
C. Cells were then washed once in PBS. During 
this time Biomag goat anti-mouse magnetic beads (Qiagen, West Sussex, UK) were 
washed by placing 5 ml of beads (in a 15 ml Falcon tube) next to a magnet. Once the 
beads were attracted to the side of the tube, the storage solution was poured away and 
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the beads were resuspended in 5 ml of R10. The cells were then added to the beads 
and incubated for a further 30 minutes at 4
o
C. During this time any labelled cells bind 
to the antibodies on the beads. To select for the unlabelled cells, the cell/bead mixture 
was placed in a magnetic field and the beads were allowed to settle on the side of the 
tube. The remaining suspension was then poured into a fresh tube and this process 
was repeated to ensure all beads were removed. Usually this required 2 repeats, or 
until no residue could be observed on the tube wall. The cells were then counted. 
 
2.2.7. Stimulation of Human T cells 
 
Following isolation and counting, human T cells were plated in a 6 well plate 
containing supplemented R10 medium. T cells were stimulated using a combination 
of anti-CD3/CD28 beads (Dynal) and phytohaemaglutinin (PHA) (Sigma-Aldrich, 
Dorset, UK). Anti-CD3/CD28 beads were added at 3 μl per 2x106 T cells. PHA was 
added at a concentration of 5 μg/ml. T cells were then incubated at 37oC, 5% CO2, for 
the length of time considered optimal for different cell surface markers to be 
expressed. 
 
2.2.8. Isolation of CD14 +ve cells from Peripheral Blood or Ascitic mononuclear 
cells 
 
CD14 +ve cells were isolated using a magnetic bead positive selection technique. 
PBMCs or AMCs were re-suspended in pre-chilled MACS buffer and anti-CD14 
microbeads (Miltenyi Biotech, Surrey, UK) were added (200 µl per 10
7
 cells in 3ml of 
buffer). The cells were incubated at 4
o
C on a roller for 30 minutes and then washed in 
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MACS buffer three times. Up to 10
7
 cells were then re-suspended in 1 ml of MACS 
buffer to pass through an MS separation column (Miltenyi Biotech) which was placed 
in a magnetic field. MS columns were first washed with 500 µl of MACS buffer, the 
labelled cell suspension was then applied to the column and the unbound cells were 
allowed to pass through and collected. The column and the bound cells were then 
washed a further three times with 500 µl MACS buffer. The cells were eluted in 1ml 
of R10 media by adding the media to the column and then flushing the column with 
the plunger provided. CD14 +ve cells were either then used in experiments as 
monocytes or differentiated into dendritic cells by culturing with 10ng/ml of IL-4 
(Invitrogen) and GM-CSF (First Link) for six days changing the media every other 
day. For mature dendritic cells, 10 ng/ml of both IL-1β and TNF-α (Peprotech, 
London, UK) were added to the culture media for 24-48 hours following the previous 
six days of culture. 
 
2.2.9. Tritiated Thymidine (
3
H)  Incorporation Proliferation Assays 
 
3
H labelled thymidine was used to measure the proliferation of T cells in mixed 
lymphocyte reactions (MLR) or proliferation assays. T cells were plated into 96 well 
plates at a concentration of 2x10
6
 cells/ml and stimulated with either anti-CD3/CD28 
beads or a stimulator cell (cell type depending on what experiment was being carried 
out) and incubated for the length of time required for the specific experiment. 
Blocking antibodies were also  added at this point if required, see Results section for 
details. 
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On the day of analysis of proliferation 
3
H thymidine was added to each well at a 
concentration of 1 µCi/well and the cells were incubated for a further eighteen hours 
before harvesting or freezing. Cells were harvested (Harvester 96 MACH III M, TOM 
TEC)  (Receptor Technologies, Adderbury, UK) onto a filter mat and counted using a 
Wallac Trilux 1450 Microbeta liquid scintillation counter (Perkin Elmer, UK).  
 
2.2.10. Carboxyfluorescein succinimidyl ester (CFSE) labelling 
 
CFSE (Sigma Aldrich) is diluted to a working concentration of 1 mM in pre-warmed 
PBS. Cells (maximum of 1x10
7
) to be labelled are washed three times in pre-warmed 
PBS and then re-suspended in the 1ml of the diluted CFSE. The cells are incubated in 
the dark on a roller for 8-10 minutes at 37
o
C. To stop the labelling, cells are washed in 
R10 media. Cells are washed twice in PBS and then resuspended in R10 media. CFSE 
labelling efficiency is checked using FL-1 channel on a BD FACSCalibur flow 
cytometer (Becton Dickinson Biosciences, UK). 
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2.3. DNA Cloning Methods 
2.3.1. RNA Extraction 
 
Around 5x10
6
 T cells were harvested and washed 3 times in PBS. Cells were then 
pelleted following centrifugation at 3,000 x g for 5 minutes, and then resuspended in 1 
ml of TRI-reagent (Invitrogen). Following a 5 minute incubation at room temperature, 
200 μl of chloroform (Sigma-Aldrich) was added to the sample, which was then 
vortexed for 15 seconds and then incubated for 5 minutes at room temperature. 
Following centrifugation at 3,000 x g for 5 minutes, the aqueous upper layer was 
collected into a fresh 1.5 ml tube. 500 μl of isopropanol (Fisher Scientific, 
Loughborough, UK) was then added to this aqueous phase and then the mixture was 
incubated at room temperature for 30 minutes. Samples were then centrifuged (3,000 
x g, 10 min, 4 ˚C) and the supernatants carefully removed.  RNA pellets were washed 
with 1 ml of 75% ethanol and then samples were centrifuged for a further 5 minutes at 
6,000 RPM at 4 ˚C. Supernatants were removed and pellets were allowed to air dry 
before being resuspended in RNase free water (Sigma-Aldrich).  RNA was quantified 
using a Biotech Photometer, UV1101 reading at a wavelength of 260 nm (WPA, 
Linton, Cambridge, UK). Reverse transcriptase polymerase chain reaction (PCR) was 
then carried out. 
 
2.3.2. Reverse Transcriptase PCR (RT-PCR) 
 
RNA extracted from T cells was then converted to cDNA as follows. A mixture 
containing 1-5 μg RNA and 1 μg oligo dT (Promega, Southampton, UK) was added to 
RNase free water (Sigma-Aldrich) to make a total volume of 16.25 μl and was added 
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to a 200 μl PCR tube. This was then heated to 65oC for 10 minutes followed by a 2 
minute incubation on ice. Following this incubation, 5 μl of 5x RT buffer, 1 μl murine 
moloney leukaemia virus (MMLV) RT enzyme (2000 unit stock) (both Invitrogen), 1 
μl dNTPs (10mM stock) (Bioline, London UK) and 0.75 μl of RNAsin (30 unit stock) 
(Promega) was added to the PCR mixture and this was incubated for 1 hour at 42
o
C. 
 
2.3.4. Polymerase chain reaction (PCR) 
 
PCR was used to clone the extracellular domain of PD-1. The reactions were set up in 
200 μl PCR tubes containing 5 μl cDNA, 5 μl of 10x Taq buffer, 2.5 μl of each primer 
(50 μM stock), 5 μl Taq polymerase enzyme (1 U/μl) (all Invitrogen). 2.5 μl MgCl2 
(40 mM stock), 1.25 μl dNTPs (10 mM stock) (Bioline) and completed to 50 μl with 
DNAse free water (Sigma-Aldrich). The reactions were then run for the following 
cycles using a Techne TC-512 thermal cycler (Techne, Stone, UK); initial 
denaturation of 95
o
C for 5 minutes followed by 30 cycles of 95
o
C for 30 seconds, 
annealing temperature Ta (Ta = Tm of primer – 5oC) for 30 seconds, 72oC for 45 
seconds. To finish, a final elongation step of 72
o
C for 5 minutes was carried out. 
 
2.3.5. Primers 
 
All sequences were based on cDNA sequences submitted to NCBI and all sequences 
above are in the 5’-3’ orientation. Primers were designed by hand to incorporate the 
extracellular domain of human PD-1 (excluding leader sequence) and purchased from 
Invitrogen (Expected product size 449bp). 
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Target  Primer Sequence 5’-3’ 
PD-1 
extracellular 
domain 
(KDEL 
fusion) 
Forward:CCTCTCGAGGGATGGTTCTTAGACTCCCCA,  
Reverse:GCATGATCGAGCGGCCGCTTGGAACTGGCCGGCTGGCCT 
 
Restriction enzyme sites in bold 
 
2.3.6. Plasmids 
pCMV/myc/ER (Invitrogen) was used to construct a PD-1 KDEL fusion protein. The 
primers to clone the extracellular domain of PD-1 were designed to contain cut sites 
for Xho I and Not I (New England Biolabs, Herts. UK). Cloning of sequences into this 
plasmid creates a fusion protein containing the ER retention amino acid sequence, 
SEKDEL (referred to as KDEL) and a myc epitope for detection of the protein. This 
plasmid contains the resistance gene for ampicillin (bacterial selection) and the 
neomycin gene for resistance against G418 (mammalian selection).  
 
pSMART2G (Donated by Prof. Myra McClure, Imperial College London) was used 
to assess transfection efficiency. The plasmid contains enhanced green fluorescence 
protein (EGFP) fused downstream of a CMV promoter. 
 
2.3.7. Ligation  
 
Digested insert and plasmid DNA was mixed together in a 1:3 ratio.  Ligation buffer 
(10x) and 1 μl of T4 DNA ligase was also added (Promega). Water was used to 
complete the total reaction volume to 20 μl and the reaction was incubated at 4oC 
overnight. 
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2.3.8. Transformation 
 
Competent DH5α bacterial cells were mixed with 10 μl of ligation mixture and 
incubated on ice for 30 minutes. The mixture was then heat shocked by incubating at 
42
o
C for 30 seconds followed by a further 2 minutes incubation on ice. Immediately 
after this heat shock, 350 μl of LB broth (Sigma-Aldrich) was added and the whole 
mixture was incubated at 37
o
C for 1 hour with shaking. The transformed cells were 
then plated on LB agar plates containing the appropriate antibiotic for selection of the 
plasmids used (see 2.3.6.). 
 
2.3.9. DNA extraction (Mini/Maxiprep) 
 
Individual colonies were chosen and grown in 3 ml of LB agar with antibiotics 
overnight at 37
o
C with shaking. The bacteria were then pelleted and the DNA 
extracted using a miniprep kit following the manufacturer’s protocol (Qiagen). 
Briefly, cells were lysed, the protein was precipitated and following micro-
centrifugation the supernatant was collected. This was then applied to a separation 
column which binds DNA. The column was then washed and the DNA eluted using 
DNAse free water.  
 
DNA was digested with the appropriate enzymes (see 2.3.6.) and the digestion 
products were analysed by agarose gel electrophoresis (2% gel containing ethidium 
bromide for UV detection of DNA). Clones which contained the correct sized insert 
were sent for sequencing (MRC Genomics, Hammersmith Hospital). 
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DNA which was found to contain the correct insert was then transformed as before 
and the DNA was extracted using the same principle as before but on a larger scale 
using a maxiprep kit (Qiagen). 
 
2.4. Non-viral Vector Transfection 
2.4.1. Lipofectin 
 
Cells were seeded 24 hours in advance in the appropriate culture plates at a cell 
number which would ensure 80-90% confluence on the day of transfection. Lipofectin 
(Invitrogen) was used at a 6:1 ratio with DNA. For a 6 well plate transfection, 12 μl of 
Lipofectin was added to 375 μl of Optimem media. In a separate tube, 2 μg of DNA 
was added to 375 μl of Optimem. These solutions were mixed together and incubated 
at room temperature for 15-45 minutes. In the meantime the cells were washed in 
Optimem to remove any serum. The DNA/Lipofectin complexes were then added to 
cells and incubated at 37
o
C for 5 hours. The transfection was stopped by removing the 
transfection mixture and replacing with complete culture media. Cells were checked 
for plasmid expression 24-48 hours later. 
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2.4.2. Nucleofection 
 
Nucleofection of SKOV-3 and OVCAR-3 cell lines was carried out using Amaxa 
Nucleofection and Cell line Nucleofector kit V (Lonza, Cologne, Germany). 
Nucleofection was carried out according to manufacturer’s protocols using 
nucleofector setting V-05 for SKOV-3 cells and T-16 for OVCAR-3 cells. Dead cells 
present following nucleofection formed a white pellet at the surface of the media in 
the nucelofection cuvette and were excluded from further culture for optimal results. 
 
2.5. Analysis of Protein Expression  
2.5.1. Western Blotting 
 
Western blotting was carried out to determine whether the expression level of 
transfected constructs. Reducing sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS PAGE) was carried out using 10% polyacrylamide gels 
containing SDS. Samples were added to loading buffer (Sigma-Aldrich) containing 
the reducing agent, β-mercaptoethanol, in a 1:1 ratio then heated to 80oC for 5 
minutes. The samples were then loaded and run at 80 V until the protein migrated to 
the bottom of the gel.  
 
Proteins were then transferred to a nitrocellulose membrane by layering the gel on top 
of the membrane and applying a positive electrode underneath the membrane, thereby 
causing the negatively charged proteins to migrate from the gel onto the membrane. 
The transfer was carried out at 100 V for 1 hour. 
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Following the transfer, the membrane was blocked by incubating in 5% w/v Marvel 
for 1 hour at room temperature with gentle agitation. The membrane was then rinsed 
with 0.1% v/v PBS Tween before incubating with the primary antibody overnight at 
4
o
C. The membrane was then washed in PBS Tween for 3x15 minutes, and the 
secondary antibody was added and further 1 hour incubation was carried out at room 
temperature. 
 
The washed membrane was then developed using ECL reagents (Amersham 
Biosciences, Amersham UK). Solution A was added to solution B in a 40:1 ratio and 
the resulting mixture was spread evenly over the membrane and incubated for 30 
seconds at room temperature. The membrane was then developed using photographic 
film (Amersham Biosciences). 
 
Antibody Conjugate Concentration Source 
Mouse anti Human myc Unconjugated 0.1 µg/ml eBioscience 
Goat anti Human PD-1 Unconjugated 0.1 μg/ml R&D Systems 
Rabbit anti Goat Ig Horse Radish 
Peroxidase 
0.5 μg/ml Dako 
Rabbit anti Mouse IgG Horse Radish 
Peroxidase 
1 μg/ml Dako 
 
Table 5: Antibodies used in Western blot experiments 
 
 
 
 
 66 
 
2.5.2. Flow Cytometry Staining 
 
Cells were washed and counted and 2.5x10
5
 cells were resuspended in 100 μl FACS 
buffer per well of a V-bottomed 96 well plate. Antibodies were added at the 
appropriate dilution (see Table 2), and the cells were incubated on ice for 30 minutes. 
Optimal antibody concentration was based on titration experiments. Following 3 
washes with FACS buffer, cells were incubated with a secondary antibody, or if the 
primary antibody was directly conjugated, cells were resuspended in around 200 μl of 
PBS. Cells which required a secondary staining were washed after 30 minutes 
incubation on ice and resuspended in FACS buffer containing the secondary antibody 
for a further 30 minutes on ice. Cells were then washed a further 3 times in FACS 
buffer and resuspended in PBS. 
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Antibody Fluorochrome Concentration Source 
Goat anti-Human PD-1 unconjugated 5 μg/ml RnD Systems 
Mouse anti-Human PD-L1 FITC 3 µg/ml BD Bioscience 
Mouse anti-Human PD-L2 R-PE 3 µg/ml BD Bioscience 
Donkey anti-Goat IgG R-PE 0.5 μg/ml RnD Systems 
Mouse anti-Human CD14 APC 3µl/10
6
 cells Caltag 
Mouse anti-Human CD80 R-PE 3µl/10
6
 cells Caltag 
Mouse anti-Human CD86 R-PE 3µl/10
6
 cells Caltag 
Mouse anti-Human CD11c R-PE 3µl/10
6
 cells Caltag 
Mouse anti-Human CD4 APC 3µl/10
6
 cells Caltag 
Mouse anti-Human CD8 R-PE 3µl/10
6
 cells Caltag 
Mouse anti-Human CD69 FITC 3µl/10
6
 cells Caltag 
Mouse anti-Human HLA-DR R-PE 3µl/10
6
 cells Caltag 
 
Table 6: Antibodies used to stain cells for Flow Cytometry. Abbreviations: FITC; 
Fluorescein Isothiocyanate, R-PE; recombinant Phycoerythrin, APC; 
Allophycocyanin 
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Isotype Conjugate Company 
Mouse IgG2a R-PE Invitrogen 
Mouse IgG1 FITC and R-PE Invitrogen 
Goat Ig unconjugated R&D Systems 
Mouse IgG1 APC Biolegend 
 
Table 7: Isotype Control Antibodies used for Flow Cytometry. Abbreviations: 
FITC; Fluorescein Isothiocyanate, R-PE; recombinant Phycoerythrin, APC; 
Allophycocyanin 
 
 
2.5.3. Cytokine Analysis using Luminex 
 
Luminex technology was used to detect cytokines in cell culture supernatants, plasma 
and ascitic supernatant samples. Samples were diluted (Plasma 1:4, cell culture 1:5, 
ascites 1:8) and 50 µl of each were plated in duplicate onto a 96 well plate, along with 
serially diluted standard cocktails of each cytokine (R&D systems). Colour coded 
microbeads, pre-coated with cytokine specific antibodies (R&D systems), were mixed 
together (depending on which cytokines were to be detected at one time) and 50 µl of 
this mixture was added to the wells with the standards and samples. This was 
incubated at room temperature for three hours on an orbital shaker. Following three 
washes in the supplied wash buffer, 50 µl of a cocktail of cytokine specific, 
biotinylated monoclonal antibodies (R&D systems) were added to each well (again, 
the specificity of the antibody depends on which cytokines were being measured at 
any one time). This was then incubated for a further one hour at room temperature 
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with shaking before washing three times in wash buffer. A final step of streptavidin-
phycoerythrin conjugate (R&D systems) was added to the wells and incubated for 
thirty minutes at room temperature with shaking. The plate was then washed a final 
three times with wash buffer and then read using a Luminex 200 machine (Biorad). 
One laser is microparticle specific and determines which cytokine is being detected; a 
second laser is used to determine the magnitude of the PE-derived signal, which is 
directly proportional to the amount of cytokine bound.  
 
2.5.4. Immunocytostaining 
 
Cells were plated onto glass cover slips and allowed to adhere before staining. Once 
cells had adhered or sufficient incubation time had passed to analyse transfected 
protein expression the cells were washed in HBSS. Following washing, cells were 
fixed in 4% formaldehyde and incubated at 37
o
C for 30 minutes. Cells were washed 
again three times in HBSS and then permeabilised using 0.2% Triton X100 and 
incubated for 30 minutes at 37
o
C. Cells were then stained with the appropriate 
antibody or endoplasmic reticulum tracker for 30 minutes at 37
o
C. Cells were finally 
washed three times in HBSS and mounted onto slides for viewing on a Leica 
Confocal TCS SP5 microscope. 
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Antibody Conjugate Concentration Company 
Anti-myc Alexa Fluor 555 5 µg/ml Biolegend 
Anti-PD-1 Alexa Fluor 647 5 µg/ml Ebioscience 
ER tracker Green marker 2 µM Invitrogen 
 
Table 8: Antibodies used to stain cells for immunocytochemistry. All antibodies 
are anti human. ER tracker was a glibenclamide BODIPY Fl green dye which shows 
excitation and emission spectra similar to that of FITC. 
 
2.5.5. Real-Time PCR (qRT –PCR) 
 
cDNA from archived tissue specimens were used in this study. 5 µg of total RNA was 
used to synthesise cDNA using the First Strand cDNA Synthesis Kit (Roche 
Diagnostics, UK). Quantitative RT-PCR was done using light cycler (ABI system) 
and primer sequences used in this study are as below (designed using Premier Primer 
software). Positive controls of OVCAR-3 ovarian cancer cell line cDNA, HUH-7 
hepatocyte cell line cDNA and negative controls were included in each analysis run. 
Experiments were performed in duplicates and average of relative mRNA expression 
was used for analysis. 
 
Primer Sequence (5’ to 3’) 
HPRT Forward GCA GAC TTT GCT TTC CTT GGT C 
HPRT Reverse CTG GCT TAT ATC CAA CAC TTC GTG 
PD-L1 Forward TAT GGT GGT GCC GAC TAC AA 
PD-L1 Reverse TGC TTG TCC AGA TGA CTT CG 
 
Table 9. Primer sequences used for Real time PCR. Human PD-L1 was used in ovarian 
cancer tumour tissues. HPRT were used as housekeeping gene used for normalisation. 
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2.6. Statistical Analysis 
All statistical analysis carried out in this thesis was done using Graphpad 5 software 
(Prism, La Jolla, USA). The test used was a Student’s T test, a parametric test 
assuming normal distribution of the data. The test performed was unpaired and two 
tailed. P values were considered significant when p< 0.05. 
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3. THE IMMUNE SYSTEM IN OVARIAN CANCER 
 
3.1. Introduction 
Ovarian Cancer is the 6
th
 most common cancer worldwide and is the most fatal 
gynaecological malignancy (Hankinson et al., 1995). Epithelial ovarian cancer (EOC) 
represents 90% of all ovarian cancers and is the focus of this chapter (Friedlander, 
1998). EOC is typically diagnosed at late stages and is treated using surgery and 
platinum based chemotherapy (Markman et al., 2004; Ozols et al., 2003). As a result 
of this late stage diagnosis the treatment regime is characterised by a period of 
remission followed by relapse of shortening duration until chemoresistance develops 
(Markman et al., 2004). Established prognostic markers currently include levels of 
CA-125 molecules which correlate with advanced stages of the disease (Canney et al., 
1984; Chauhan et al., 2006). CA-125 however is a poor marker of early stage ovarian 
cancer; 50% of early stage patient’s malignancies have elevated levels of CA-125 
compared to 90% of late stage (Nossov et al., 2008). As a result of the limitations of 
CA-125 as a prognostic marker, work is being carried out in looking for newer, 
immune system related markers.  
 
Following the observation that the presence of tumour infiltrating lymphocytes (TILs) 
correlated with improved 5 year survival rates, work has focussed on the immune 
system as a source of possible prognostic markers and potential therapeutic targets 
(Zhang et al., 2003). It is well established that the tumour creates an 
immunosuppressive microenvironment in which to survive and grow using a 
combination of suppressive cytokines, inhibitory costimulation molecules and 
regulatory T cell recruitment (Dunn et al., 2002). This is therefore the basis of this 
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chapter. Which immunosuppressive mechanisms are in place in human epithelial 
ovarian cancer, and particularly, how important are the PD-1 pathway molecules in 
the survival and growth of ovarian cancer? 
 
There has been very little work carried out on the PD-1 pathway in ovarian cancer. Of 
particular note is work carried out by Hamanishi et al. which stained paraffin 
embedded EOC tumour sections for PD-1 and its ligands. This work suggested that 
PD-L1 expression correlated inversely with overall survival rates and indicated that 
PD-L1 could be used as an independent prognostic marker in ovarian cancer 
(Hamanishi et al., 2007). 
 
This chapter will investigate the PD-1 pathway in ovarian cancer as well as the 
inhibitory molecules present in the tumour microenvironment. The aims are as 
follows: 
 
1. Investigate PD-1 expression on T cells present in EOC ascites and peripheral 
blood 
2. Investigate PD-L1 expression on antigen presenting cells in EOC ascites and 
peripheral blood. 
3. Measure cytokine concentrations present in the ascitic fluid of patients with 
malignant and benign/borderline EOC. 
4. Analyse PD-1 pathway molecules present in the tumour cell mass as well as 
common EOC cell lines 
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3.2. Results 
Ascites samples from patients with differing stages and grades of ovarian cancer were 
collected over a two year period. The immune cells present in this ascites were 
extracted by Ficoll separation and phenotyped for a number of immunological 
markers by flow cytometry. Of particular focus for this thesis I will describe PD-1 
pathway molecules on the immune cells present in ovarian cancer ascites and 
peripheral blood. 
 
3.2.1. T cells and Antigen Presenting Cells 
3.2.1.1. T cells in Ascites 
 
T cells were separated from ascites and screened for PD-1 expression using flow 
cytometry. The results were used to compare PD-1 expression on ascitic T cells from 
patients with benign/borderline tumours to those with malignant tumours. A 
representative flow cytometry profile from each patient group for PD-1 expression on 
CD8 and CD4 T cells is shown in Figure 3.1. The Figure shows an increase in PD-1 
expression on both CD4 and CD8 T cells in malignant ovarian cancer compared to 
benign ovarian cancer. The whole data set is represented in Figure 3.2 and shows a 
small, non-significant increase in PD-1 expression on malignant cases compared to 
benign cases.  
 
The gating strategy used to obtain the graphs in Figure 3.1 and 3.3, as well as the 
grouped data in figures 3.2 and 3.4 are shown in the appendix. 
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Figure 3.1: PD-1 expression on ascitic T cells. Figure shows PD-1 expression on CD4 
and CD8 T cells using flow cytometry, comparing a malignant case to a benign case. 
These data are representative of multiple experiments which are summarised in later 
Figures. Gates were set with appropriate isotype controls 
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Figure 3.2: PD-1 expression on T cells in ascites. PD-1 expression was measured 
by flow cytometry on both CD4 and CD8 T cells extracted from patient ascites. 
Benign/borderline cases (green) are compared to malignant cases (red). Overall PD-1 
expression on T cells from malignant ascites is slightly higher than on 
benign/borderline cases. Malignant n=15 (except in case of CD8 due to human error 
during staining), Benign/Borderline n=6. Statistical analysis was done using a 
Student’s T test.  
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3.2.1.2. T cells in peripheral blood 
 
T cells were extracted from peripheral blood of ovarian cancer patients and analysed 
for PD-1 expression by flow cytometry. The results of a representative case of benign 
and malignant patients are shown in Figure 3.3 and the combined data is shown in 
Figure 3.4. There is no difference in the PD-1 expression on either CD4 or CD8 T 
cells which is different to what has been observed on ascitic T cells (Figure 3.1). 
There is also a lower percentage of CD8 T cells expressing PD-1 than CD4 T cells; 
this is also different from what was observed on ascitic T cells (Figure 3.1). Therefore 
there is no difference in PD-1 expression on either CD8 or CD4 peripheral T cells 
when comparing benign/borderline vs. malignant cases. 
 
Overall there is a significantly lower level of PD-1 expression on T cells in peripheral 
blood compared to T cells in ascites. Malignant ascites PD-1 expression compared to 
malignant blood PD-1 expression gave a significant p value in a Student’s T test 
(p=0.0001). Likewise benign/borderline ascites PD-1 expression vs. benign/borderline 
blood PD-1 expression gave a P value of p<0.0001.  
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Figure 3.3.: PD-1 expression on peripheral blood T cells. Figure shows PD-1 
expression on CD4 and CD8 peripheral blood T cells using flow cytometry, comparing 
a patient with malignant ovarian cancer to a patient with benign ovarian cancer. These 
data are representative of multiple experiments which are summarised in later Figures. 
Gates were set using appropriate isotype controls 
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Figure 3.4: PD-1 expression on T cells from peripheral blood. PD-1 expression was 
measured on CD8 and CD4 T cells from peripheral blood taken from patients with 
benign/borderline (green) and malignant (red) ovarian cancer. The PD-1 expression on these T 
cells is similar in both cases. Malignant n=15, Benign/Borderline n=15. 
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3.2.1.3. Antigen Presenting Cells in Ascites  
 
Immune cells were separated from ascites and stained for PD-L1 and CD14 
expression. The results are shown in Figure 3.5. Part A shows an example of PD-L1 
expression on CD14 cells on a patient with benign ovarian cancer vs. a patient with 
malignant ovarian cancer. PD-L1 shows a significantly large upregulation (62%) in 
the malignant case compared to the benign case which shows no PD-L1 expression. 
The total data from all patients’ ascites is shown in part B and again shows a 
significantly higher level of PD-L1 on malignant cases compared to benign/borderline 
cases.  
 
PD-L2 expression was examined on the same patients, however it showed little or no 
expression in both malignant or benign/borderline cases (data not shown).  
 
The gating strategy and isotype control settings for figures 3.5 and 3.6 are shown in 
the appendix. All statistics were carried out using a Students’ T test. 
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Figure 3.5: PD-L1 expression on 
antigen presenting cells from 
ascites. Part A shows a 
representative case of APCs from 
patients with benign (n=6) and 
malignant (n=15 for CD14, n=10 for 
CD11c) ovarian cancer. There is a 
very high expression of PD-L1 on 
APCs from malignant cases 
compared to benign. Part B shows 
PD-L1 expression on APCs from all 
data collected. Benign/borderline 
cases are shown in green and show 
low expression of PD-L1 compared 
to the significantly higher PD-L1 
expression on APCs from malignant 
patients (red). The X axis labels in 
part B labelled as “CD14/CD11c”, 
“CD14/PD-L1” and “CD11c/PD-
L1” refer to double positive cells 
e.g. CD14+ PD-L1+ cells.  
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3.2.1.4. Antigen Presenting Cells in Peripheral Blood 
 
Following Ficoll separation of immune cells from patient blood, CD14 and PD-L1 
expressing cells were analysed by flow cytometry. The results in Figure 3.6A show a 
representative case from a patient with benign ovarian cancer and patient with 
malignant ovarian cancer. Similarly to the antigen presenting cells present in ascites, 
the malignant APCs show a significantly higher amount of PD-L1 expression 
compared to the benign case. The combined data is shown in part B and also includes 
PD-L1 expression on CD14 cells from healthy women. Healthy and benign/borderline 
cases show little to no PD-L1 expression whereas the malignant patients show 
significantly higher PD-L1 expression (~73%).  
 
As with ascites APCs, little PD-L2 was found to be expressed on peripheral blood 
APCs (data not shown). 
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Figure 3.6: PD-L1 expression on 
antigen presenting cells from 
peripheral blood. Part A shows a 
representative case of APCs from a 
patient with benign ovarian cancer and a 
patient with malignant ovarian cancer. 
There is a very high expression of PD-
L1 on APCs from malignant cases 
compared to benign. Part B shows PD-
L1 expression on APCs from all data 
collected. Benign/borderline cases are 
shown in green and show low 
expression on PD-L1 compared to the 
significantly higher PD-L1 expression 
on malignant cases (red). Healthy 
patient APCs are shown in blue and 
show no expression of PD-L1 in a 
similar manner to benign/borderline 
cases. The X axis labels in part B 
labelled as “CD14/CD11c”, “CD14/PD-
L1” and “CD11c/PD-L1” refer to 
double positive cells e.g. CD14+ PD-L1 
+ cells. Malignant n=10 (CD11c) n=14 
(CD14), Benign/Borderline n=15 
(CD14) n=10 (CD11c), Healthy n=6. 
Ststistics were carried out using a 
Student’s T Test. 
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Based on the above results it was decided to test the physiological significance of this 
increased PD-L1 level on ascitic monocytes using an in vitro functional assay. 
Monocytes from benign/borderline or malignant tumour ascites were cultured in a 
1:10 ratio with healthy CD3/CD28 bead stimulated T cells with and without the 
presence of a blocking anti-PD-1 antibody. Proliferation was measured by thymidine 
incorporation on days 3 and 5. The results are shown in Figure 3.7, and show that the 
presence of malignant tumour ascitic monocytes suppresses T cell proliferation to a 
greater degree than benign/borderline tumour ascitic monocytes on day 5 (part A). 
The suppression noted in both cases can be partially, although not fully, reversed in 
the presence of the PD-1 blocking antibody suggesting that the suppression observed 
due to ascitic monocytes is at least partially PD-L1 mediated. Part B shows stimulated 
T cells cultured with normal healthy monocytes from peripheral blood. The presence 
of these monocytes does not suppress T cell proliferation. 
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Figure 3.7: Ascitic monocytes cultured with normal T cells. Part A shows stimulated T cells 
cultured with malignant tumour ascitic (red 292) monocytes and borderline tumour ascitic (green 
291) monocytes with (solid line) or without (dashed line) PD-1 blocking antibody. Compared to 
stimulated T cells cultured alone (blue), both sets of monocytes suppress T cell proliferation. 
Malignant tumour monocytes suppress proliferation more than borderline tumour monocytes and 
both can be partially reversed using a PD-1 blocking antibody (solid line). This experiment is 
representative of 5 ascitic monocyte co-cultures. Part B shows stimulated T cells cultured with 
healthy monocytes from peripheral blood (green lines H1). There is no inhibitory effect compared 
to T cells cultured alone (blue). This Figure is representative of 3 healthy monocyte controls. 
Statistics were carried out using a Student’s T Test. 
P<0.0001 
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3.2.2. The Tumour Microenvironment 
3.2.2.1. Cytokines in the tumour environment 
In the case of ovarian cancer we are able to study the tumour microenvironment by 
studying the ascites available to us. This consists of tumour cells, immune cells and 
soluble factors which will contribute to an immunosuppressive environment for the 
immune system. It was therefore decided to remove all cells present in the ascites and 
study the soluble supernatant. Luminex multiplex technology was used to 
simultaneously analyse the concentrations of 14 different cytokines present in the 
ascites and plasma of a range of patients with malignant and benign/borderline 
tumours. Cytokines to be analysed were chosen based on their function, IL-2, IL-4, 
IL-17, IL-13 and IL-12 were chosen due to their known role in T cell responses. IFNγ 
was chosen as it is involved in Th1 responses and is known to upregulate PD-L1. 
GM-CSF is involved in dendritic cell maturation. IL-1β, IL-6 and TNF-α are all pro-
inflammatory cytokines. IL-8 and VEGF were chosen due to their role in 
angiogenesis. IL-10 and TGF-β were chosen due to their immunosuppressive activity. 
 
The results are shown in the following four Figures (Figure 3.8, 3.9, 3.10, 3.11). The 
first observation during this analysis was that plasma samples run in parallel to the 
ascitic samples were below the limit of detection for all cytokines tested (plasma data 
not shown). The cytokines expressed at very low levels are shown in Figure 3.8, these 
include IL-2, IL-4, GM-CSF (majority negative) and IFN γ and IL-17 which are 
expressed at a low but detectable concentration. Figure 3.9 shows the concentrations 
of IL-6, IL-8 and VEGF which show the highest level of all cytokines measured. All 
are expressed in the nanogram/ml range. IL-8 and VEGF show similar levels of 
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expression in benign/borderline and malignant cases, whereas IL-6 was detected at a 
higher, yet non-significant level in benign/borderline cases compared to malignant. 
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Figure 3.8: Concentrations of a range of cytokines in ovarian cancer ascites. The graph shows 
the levels of IL-4, IL-17, IFN γ, IL-2 and GM-CSF in the ascitic supernatant of malignant and 
benign/borderline cases of ovarian cancer. All are expressed at either very low levels or not at all. 
There are no significant differences between supernatant from malignant tumours vs. supernatant 
from benign/borderline tumours. Benign n=5 Malignant n=20 
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Figure 3.9: Concentration of IL-8, IL-6 and vascular endothelial growth factor 
(VEGF) in ovarian cancer ascites. The graph shows the levels of IL-8, IL-6 and VEGF 
in the ascitic supernatant of malignant and benign/borderline cases of ovarian cancer. 
There is an higher IL-6 concentration measured in benign/borderline tumour supernatant 
compared to malignant, this is non-significant. The are no significant differences 
between VEGF and IL-8 concentrations in supernatant from malignant tumours 
compared to supernatant from benign/borderline tumours. Benign n=5 Malignant n=20 
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Figure 3.10: TNF-α and IL-1β concentrations in ascitic supernatant. The graph 
shows the concentrations of TNF-α and IL-1β in benign/borderline and malignant 
ovarian cancer ascites. There are no significant differences in the concentrations of 
cytokines in supernatant from malignant vs. benign/borderline tumours. Benign n=5 
Malignant n=20 
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Figure 3.11: TGF-β and IL-10 concentrations in ascitic supernatant. Part A shows IL-10 
concentrations in ascitic supernatant of benign/borderline ovarian cancer patients vs. 
malignant. The graph shows a statistically significant increase in IL-10 in supernatant from 
malignant tumours compared to benign/borderline tumours (p<0.05). Part B shows TGF-β 
concentrations in ascitic supernatant of benign/borderline cases vs. malignant cases. There is a 
significant increase in malignant vs. benign/borderline cases (p<0.05). Benign n=8 (IL-10) 
n=9 (TGF-β), Malignant n=20 (IL-10) n=26 (TGF-β). Statistics were carried out using a 
Student’s T Test.  
A 
B 
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TNF-α and IL-1β concentrations are shown in Figure 3.10 and are in the low 
picogram/ml range. There is a slight increase in malignant tumour TNF-α although 
this is not significant. IL-1β levels remain similar between benign/borderline and 
malignant cases. The final Figure (3.11) of the luminex data shows the concentrations 
of TGF-β and IL-10, both of which are considered immunosuppressive cytokines. IL-
10 is expressed at moderate levels compared to the other cytokines and malignant 
cases show significantly more IL-10 than benign/borderline cases (Figure 3.11A). 
Similarly with TGF-β, malignant cases have significantly higher TGF-β than 
benign/borderline cases (Figure 3.11B). TGF- is also expressed at a higher level than 
IL-10 (nanogram/ml vs. picogram/ml respectively). 
 
IL-12 and IL-13 were also measured in 40 cases of ascitic supernatant, however no 
detectable levels of either were found and the data is not shown. 
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3.2.2.2. Effect of ascites supernatant on T cells 
 
It was hypothesised that due to the level of immunosuppressive cytokines present in 
the ascitic supernatant, culturing normal CD3/CD28 bead stimulated T cells in a range 
of supernatants would have a suppressive effect on their ability to proliferate. Five 
malignant supernatants and 3 benign/borderline supernatants were chosen at random 
and T cells were cultured in dilutions (with RPMI) of each ranging from 100% 
supernatant to 0% supernatant. Proliferation was measured by thymidine 
incorporation on day 5 and the results are shown in Figure 3.12. Part A shows the 
proliferation for the full range of dilutions. The first observation is that proliferation is 
generally lowest at 100% supernatant and increases as the supernatant is diluted 
towards 0%. Secondly the suppressive effect of this supernatant is more pronounced 
amongst malignant cases (red) compared to benign/borderline (blue). Part B shows 
the proliferation at 40% supernatant, a mid range dilution, and statistically compares 
malignant (red) with benign/borderline (blue). This dilution was chosen as it is a mid-
range dilution, at all other dilutions all 5 malignant tumour supernatants also result in 
a greater inhibition of T cell proliferation than the 3 benign/borderline tumour 
supernatants. This Figure shows T cells are significantly suppressed at 40% dilution in 
malignant compared to benign/borderline tumour supernatants (p<0.05). 
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Figure 3.12: T cells cultured in ascitic supernatant. Part A shows normal T cells 
stimulated by CD3 CD28 beads and cultured in a range of malignant (red) or 
benign/borderline (blue) tumour supernatants ranging from 100% to 0% dilutions. Part 
B shows proliferation at 40% ascitic supernatant and statistically compares malignant 
and benign supernatant, there is significantly more inhibition of T cell proliferation by 
malignant tumour supernatant compared to benign/borderline  (p<0.05). Statistical 
analysis was carried out using a Student’s T test. 
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At the time of carrying out the experiment in Figure 3.12, IL-10 concentrations of the 
supernatants were known, it was therefore hypothesised that IL-10 was the cause of 
the suppression observed in the malignant cases. The experiment was repeated with 
supernatant chosen based on the IL-10 concentrations. Two cases with high IL-10 
(>100 pg/ml), two with low IL-10 (<50 pg/ml) and one mid range (50-100 pg/ml) 
case was chosen. All supernatants were diluted to 40% with RPMI medium and 
normal, CD3/CD28 bead stimulated T cells were cultured in the supernatant for 5 
days with or without an IL-10 blocking antibody (Ebioscience). The results are shown 
in Figure 3.13. All supernatants show a suppression of T cell proliferation with those 
supernatants with high IL-10 showing the most suppression. Low and mid range 
supernatants show suppression although not to the same extent as the high 
supernatants. The presence of the IL-10 blocking antibody has a slight non significant 
effect on reversing the suppression although it does not return the proliferation to the 
level of the bead stimulated T cells in media alone. This result suggests IL-10 may be 
partially responsible for the suppression observed when activated T cells are cultured 
in ascitic supernatant. On the other hand, although IL-10 is elevated in cases where 
suppression is observed it may be that it is not the cause of suppression and is perhaps 
a marker of a suppressive environment. 
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Figure 3.13: T cells cultured in ascitic supernatant with IL-10 blocking. Ascitic 
supernatants were chosen which contained either high (>100 pg/ml), mid (100-50 
pg/ml) or low (<50 pg/ml) IL-10 and diluted to 40% with RPMI medium. T cells were 
activated with CD3/CD28 beads and cultured in the supernatants for 5 days with 
(green) or without (blue) anti-IL-10 blocking antibody. The results show a 
suppression of proliferation of the T cells in all supernatants, although suppression is 
highest in the high IL-10 supernatants. The presence of the antibody increases 
proliferation although not significantly. 
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T cells were cultured in malignant and benign/borderline supernatants again in order 
to determine whether cytokines present in the ascites could upregulate PD-1. T cells 
were incubated in 100% supernatant for 72 hours without stimulation and then PD-1 
expression was analysed by flow cytometry. The results are shown in Figure 3.14. 
Part A shows the PD-1 expression on T cells following 72 hours culture in malignant 
or benign/borderline supernatant. There is no difference between the experimental 
groups. Part B shows PD-1 expression on unstimulated T cells cultured for 72 hours 
in RPMI media. The percentage of T cells expressing PD-1 in this control is around 
40% which is similar to the PD-1 level observed when T cells were cultured in the 
ascitic supernatants (part A). Therefore the presence of ascites does not cause 
upregulation of PD-1 on T cells. 
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Figure 3.14: PD-1 expression on T cells cultured in ascitic supernatant. Part 
A shows PD-1 expression on unstimulated T cells cultured in malignant (n=6) and 
benign/borderline (n=2) tumour supernatant after 72 hours. Part B shows PD-1 
expression on unstimulated T cells cultured in media for 72 hours. T cells in 
ascitic supernatant show no significant upregulation of PD-1 compared to media 
cultured T cells. 
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3.2.2.3. Effect of ascites supernatant on APCs 
 
In a similar manner to culturing T cells in ascites supernatant to measure PD-1 
expression, monocytes were culture in ascitic supernatant to see the effect on PD-L1 
expression. Previous data in this chapter shows monocytes from patients’ ascites with 
malignant ovarian cancer have higher level of PD-L1 than those monocytes from 
patients with benign/borderline ovarian cancer (Figure 3.5.). We hypothesised that 
this upregulation may be due to cytokines expressed in the tumour environment. 
Monocytes were extracted from normal blood by magnetic separation and cultured in 
ascites supernatant from patients with benign or malignant ovarian cancer. PD-L1 was 
measured at 0, 2, 6 and 8 hours. Media containing recombinant IL-10 or IFNγ were 
used as controls. The results are shown in Figure 3.15.  PD-L1 upregulation is 
observed from 4 hours and 8 hour incubation times on monocytes which were 
cultured in media containing IL-10 and IFNγ suggesting a role for these cytokines in 
controlling PD-L1 expression. This upregulation was also observed with the same 
kinetics on monocytes cultured in malignant ascites supernatant, although not on 
those cells cultured in benign ascites supernatant. This suggests a possible reason for 
the results observed in Figure 3.5 showing high expression of PD-L1 on monocytes 
from the ascites of patients with malignant ovarian cancer. Possible future 
experiments could look at blocking IL-10 and IFNγ and trying to reverse this 
upregulation of PD-L1 on the monocytes. 
 
 
 
  
Figure 3.15. PD-L1 expression on monocytes cultured in ascites supernatant. Monocytes were extracted from healthy blood using 
positive selection for CD14+ cells. These monocytes were cultured in either medium alone, benign ascites supernatant, malignant 
ascites supernatant or medium supplemented with recombinant IL-10 or IFNγ (100U/ml of each). Following incubations of 0, 2, 4 and 
8 hours cells were harvested and analysed for PD-L1 expression by flow cytometry. PD-L1 expression is increased from 4 hours 
onwards when IL-10 or IFNγ is added to the medium or if the cells are cultured in malignant ascites supernatant. There is no 
upregulation of PD-L1 on monocytes cultured in benign supernatant throughout the incubation period. This is representative of 2 
experiments. Statistics were carried out using a Student’s T Test. 
P<.0.001 
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3.2.3. The Tumour Mass 
 
The final section of this chapter deals with the tumour itself. The immune system and the 
tumour microenvironment have been phenotyped for PD-1 pathway members and a range 
of cytokines, so the tumour mass was screened for PD-1 pathway members, immune cell 
infiltrates and to see if the presence of tumour cells in an in vitro model had any effect on 
the phenotype of immune cells. 
 
Attempts were made at isolating primary tumour cells based on epithelial cell adhesion 
molecules (EpCAM) expression using a MACS seperation technique (Miltenyi). EpCAM 
has been shown to be overexpressed on ovarian cancer cells, and has been reported to be 
a prognostic marker in EOC (Spizzo et al., 2006). Briefly, cells were isolated from ascites 
and labelled with an anti-EpCAM PE conjugated antibody, a secondary anti-PE antibody 
conjugated to a magnetic bead was then used to magnetically select for epcam positve 
cells. Unfortunately, yields were very low using this technique and were often 
contaminated with fibroblasts. As such we were unable to use primary tumour cells in 
functional experiments and instead relied on ovarian cancer cell lines which were 
supplied by the laboratory of Dr Sadaf Ghaem-Maghami. For phenotyping experiments, 
frozen tumour sections and paraffin embedded sections were used in quantitative PCR 
and immunohistochemistry experiments respectively (again supplied by Dr. Ghaem-
Maghami). 
 
 
 102 
 
3.2.3.1. PD-L1 expression on Tumour cells 
 
mRNA from a range of frozen tumour sections and normal ovaries was isolated and used 
to measure PD-L1 expression by quantitative real time PCR. The results of the PD-L1 
mRNA levels are shown in Figure 3.16. The Figure shows that compared to normal 
ovary; borderline, serous and endometrioid cases have a higher level of expression of PD-
L1. Endometrioid tumours express particularly high levels of PD-L1 message and show 
the highest level amongst the histotypes tested. Clear cell carcinomas show similar levels 
of PD-L1 to normal ovary (it should be noted that only one clear cell case was used and 
analysed in this experiment, so conclusions relating to clear cell cases will be unreliable). 
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Figure 3.16. PD-L1 mRNA expression in the tumour mass. mRNA was extracted 
from frozen tumour samples or normal ovary. cDNA was produced from mRNA and 
used as a template for Real time PCR with specific primers for PD-L1. HPRT was 
used as a control gene and the results in the graph represent the ratio of PD-L1 to 
HPRT. Normal ovary shows little PD-L1 expression. Borderline tumour mass shows 
a higher PD-L1 level than normal ovary. Malignant cases have been subdivided into 
different histotypes, serous shows a slightly higher level than borderline. 
Endotmetrioid tumour samples have the highest level of PD-L1 whereas clear cell 
cases show a comparable level to normal ovary. Normal ovary n=1; borderline n=3; 
serous n=20; endometrioid n=2; clear cell n=1 
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3.2.3.2. PD-L1 expression on Ovarian Cancer cell lines 
 
Courtesy of the laboratory of Dr. Sadaf Ghaem-Maghami we had access to ovarian 
cancer cell lines of differing histology. These cell lines were intially screened for PD-L1 
expression by flow cytometry and subsequently chosen to be used in functional 
experiments as a surrogate tumour model. The flow cytometry screening is shown in 
Figure 3.17. The data is split into two different histotypes, serous and clear cell 
carcinomas. None of the clear cell carcinoma lines express PD-L1 constitutively and only 
OVISE and SMOV upregulate PD-L1 in response to a 48 hour incubation with IFN γ, 
although both still show less than 10% expression. Serous cell lines show an overall 
higher level of PD-L1 expression with all five cell lines constitutively expressing the 
ligand, albeit at differing levels. All serous cell lines upregulate PD-L1 following IFN γ 
treatment. This is consistent with the real time PCR data in Figure 3.16., where clear cell 
carcinomas express low levels of PD-L1 message compared to serous and other 
histotypes. 
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Figure 3.17: PD-L1 expression on ovarian cancer cell lines. Ovarian cancer 
cell lines from either serous or clear cell histotypes were screened for PD-L1 
expression by flow cytometry. Cell lines were either incubated for 48 hours in 
RPMI medium alone, or RPMI medium containing 10 ng/ml IFN γ.  
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3.2.3.3. Do Ovarian Cancer cell lines affect the phenotype of immune cells? 
 
Following the observation at the start of this chapter (Figures 3.5 and 3.6) that CD14 
positive cells in patients with malignant tumours had high levels of PD-L1 expression, it 
was hypothesised that this might be due to the presence of the tumour cells. Therefore it 
was decided that a co-culture experiment should be set up in which CD14+ cells isolated 
from peripheral blood would be cultured with the OVCAR-3 ovarian cancer cell line to 
investigate whether the presence of the tumour cell could cause a change in the PD-L1 
expression level on the monocyte. The data is shown in Figure 3.18. Monocytes were 
cultured in either a 2:1 or 5:1 ratio with OVCAR-3 for either 24 or 48 hours. Monocytes 
were then analysed for PD-L1 expression by flow cytometry. Neither ratio of 
monocytes:OVCAR-3 upregulate PD-L1 compared to the negative controls (monocytes 
alone). This experiment was also repeated with SKOV-3 cell line and showed a similar 
result. This suggests that the presence of the tumour cell in this experiment does not 
affect the phenotype of the monocytes. This could be the case in vivo where other factors, 
other than the presence of tumour cells, may lead to upregulation of PD-L1.  
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Figure 3.18: PD-L1 expression on monocytes co-cultured with OVCAR-3 cells. 
Monocytes from peripheral blood were cultured with OVCAR-3 in either a 2:1 or 5:1 
ratio for 24 or 48 hours. PD-L1 expression was then analysed on monocytes by flow 
cytometry. The presence of OVCAR-3 cells does not upregulate PD-L1 on monocytes. 
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In a similar manner to the above experiment we investigated the effect of co-culture of T 
cells and ovarian cancer cell lines on the expression of PD-1 on the T cell. T cells were 
isolated from peripheral blood and cultured with OVCAR-3 and SKOV-3 in a 10:1 ratio 
for 72 hours. T cells were unstimulated in the co-cultures although a control with 
CD3/CD28 bead stimulated T cells was included. Human embryonic kidney cells were 
used as a control in the co-cultures as an example of a non ovarian cancer cell line. The 
data is shown in Figure 3.19. Part B shows bead stimulated T cells which show the 
expected upregulation of PD-1. Parts C, D, and E show the T cells co-cultured with 
SKOV-3, OVCAR-3 and HEK respectively. The presence of the three cell lines has no 
effect on increasing PD-1 expression on the T cells compared to the unstimulated T cell 
control (part A). Co-culture with OVCAR-3 results a decrease in T cell PD-1 expression.  
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Figure 3.19.: PD-1 expression on T cells co-cultured with ovarian cancer cell lines. T cells were 
isolated from peripheral blood and co-cultured with either SKOV-3 (C), OVCAR-3 (D), or HEK (E) 
cell lines. PD-1 expression was analysed by flow cytometry after 72 hours and compared to 
unstimulated (A) and CD3/CD28 bead stimulated T cells (B). This is representative of three 
experiments. 
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3.3. Discussion 
 
Ovarian cancer is the most common of gynaecological malignancies. Due to a lack of 
obvious symptoms, it is currently routinely diagnosed at advanced stages. This has lead to 
interest in newer, more reliable diagnostic and prognostic markers such as immune 
system members. A few studies have demonstrated that immune factors such as the 
presence of tumour infiltrating lymphocytes can be used as alternative markers for 
prognosis. As such this immune involvement opens up a broader area to explore for 
markers and targets for treatment.  
 
The focus of this chapter was to study the immune system involvement in ovarian cancer 
and in particular the negative co-stimulation pathway, PD-1. We set out to look for 
expression of PD-1 pathway members on all factors associated with the tumour 
microenvironment. We also extensively measured the concentration of cytokines present 
in the environment which may have a role in general immunosupression or more 
specifically, regulation of the PD-1 pathway molecules. What emerges is a detailed 
picture of the immunosuppressive factors that play a role in the survival and progression 
of ovarian cancer. 
 
3.3.1. T cells and APCs 
Immune cells were extracted from ascites and peripheral blood of patients and 
phenotyped for a range of markers. Of particular interest to this project was the PD-L1 
pathway molecule expression on the T cells and the antigen presenting cells. PD-1 
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expression was shown on both CD4 and CD8 T cells from the blood and ascites. In blood 
the expression of PD-1 on the T cells was similar in both patients with benign/borderline 
and malignant tumours. However in ascites there was a small increase in PD-1 on 
malignant T cells. When comparing PD-1 expression on T cells from the ascites to T cells 
in the blood there was a significant upregulation on ascitic T cells compared to 
benign/borderline (malignant ascites vs. blood p=0.0001; benign/borderline ascites vs. 
blood p<0.0001). Patients with chronic infections such as HIV and HCV have been 
shown to have elevated levels of PD-1 on T cells which may contribute to their exhausted 
nature. It has been hypothesised in the literature that this observation may be apparent in 
conditions where T cells are exposed to antigen for a long period of time such as cancer 
(Barber et al., 2006; Day et al., 2006). It is therefore surprising to note that the T cells 
found in malignant ovarian cancer ascites express similar levels of PD-1 as those T cells 
found in benign/borderline cases. 
 
Antigen presenting cells were screened for PD-L1 expression, and significantly higher 
levels were observed in both blood and ascites. The PD-L1 expression on 
benign/borderline and healthy CD14 positive cells in blood was less than 10%, whereas 
the ascitic CD14 populations were on average around 75%. This is again shown in 
ascites, with benign/borderline cases expressing very low PD-L1 and malignant patients 
expressing an average of around 75%. This is perhaps the most striking result of this 
chapter and a clear correlation of PD-L1 with malignancy. Future work here would be to 
maintain collection of data showing PD-L1 expression on APCs in patients with ovarian 
cancer and correlate the expression with long term progression of the tumour in terms of 
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stage and/or grade. This would give valuable information as to the use of PD-L1 
expression on APCs as a prognostic marker in ovarian cancer. 
 
To demonstrate the physiological relevance of this PD-L1 expression on the antigen 
presenting cells associated with the tumour, ascitic monocytes were used in functional 
experiments with normal healthy T cells. CD14 positive cells were isolated from ascites 
and cultured with bead stimulated T cells from blood. Compared to controls, the presence 
of ascitic CD14 cells suppressed T cell proliferation. Furthermore, this suppression could 
be partially reversed by addition of a PD-1 blocking antibody to the culture. From the 
example shown in Figure 3.7, ascitic monocytes from benign/borderline patients also 
suppress T cell proliferation but to a lesser degree. Healthy monocytes had no 
suppressive or stimulatory effect demonstrating that this suppression was unique to 
monocytes associated with the tumour. The partial reverse of this suppression by the PD-
1 antibody suggests that this suppressive effect is due, in part, to PD-L1 expression on the 
monocytes. These data adds functional significance to the PD-L1 expression data 
described previously and is a likely method of immunosuppression by the tumour 
although not the only method. 
 
3.3.2. Tumour Microenvironment 
Studies into the cytokines associated with ovarian cancer have been carried out, however 
no one study has looked at an extensive range of cytokines associated with the ascites of 
ovarian cancer patients. Also many studies look into the cytokines expressed by ovarian 
cancer cell lines which is not always a good indication of what is expressed in the tumour 
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environment itself. We looked at a range of cytokines associated with 
immunosuppression, Th1, Th2 and Th17 responses, granulocyte differentiation and 
angiogenesis. Cytokines associated with inflammation and T cell responses were low or 
non expressed such as IFNγ, IL-2, IL-4, IL-12, IL-17, TNFα and IL-1β. This was 
expected in malignant cases as these cytokines are typically associated with healthy T cell 
responses and inflammation which would lead to anti-tumour immune responses. 
However these were also expressed at low levels in the benign/borderline cases. Those 
cytokines which were expressed to a higher degree are VEGF, IL-8 and IL-6. VEGF is an 
important growth factor in angiogensis, and it is of no surprise that this cytokine is 
expressed in the tumour environment. In addition it has been shown that VEGF directly 
correlates with the level of myeloid derived suppressor cells in the blood, which could be 
of importance in the suppression of the immune system during cancer (Melani et al., 
2003). IL-8 is also associated with angiogenesis and has been shown in mouse model of 
ovarian cancer to have a growth potentiating activity (Chikazawa et al., 2008; Xu and 
Fidler, 2000). IL-6 is a pro-inflammatory cytokine usually released by macrophages and 
is involved in the acute phase response. Its expression in this study was higher in patients 
with benign/borderline tumours compared to those with malignant tumours. This 
reduction in malignant cases could be a mechanism to avoid immune attack. The most 
interesting observations in this profiling of cytokines were that of the concentrations of 
TGFβ and IL-10. Both of these cytokines are regarded as potent immunosuppressive 
agents and are often associated with regulatory T cell mediated suppression. Both of 
these cytokines are expressed in the ascites of ovarian cancer patients, although TGF β 
exhibits a 100 fold higher expression level than IL-10 and is perhaps the more important 
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of the two in this instance. Both of these cytokines also show significantly higher 
expression in malignant vs. benign/borderline cases. 
 
To investigate the potential immunomodulatory role of the tumour environment on T 
cells activity, an in vitro assay was set up in which T cells isolated from human blood 
were stimulated with CD3 CD28 beads and cultured in different dilutions of ascitic 
supernatant. As the ascitic supernatant is diluted from 100% to 0% the proliferation of the 
T cells increases, furthermore those supernatant from malignant patients suppress T cell 
proliferation to a greater degree than supernatant from benign/borderline patients. This is 
good evidence that the cytokines described in the supernatant play a functional role in 
suppressing T cells. This effect is not due to the upregulation of PD-1 on the T cells as T 
cells which were cultured in supernatant showed no upregulation in PD-1 expression 
from either malignant or benign/borderline supernatants compared to unstimulated T cell 
in media. 
 
The ascites supernatant did show an effect on the PD-L1 expression on monocytes. In a 
similar experiment to that described with the T cells above, monocytes were separated 
from blood and cultured in either malignant or benign supernatant. As positive controls 
monocytes were cultured in media containing IL-10 or IFNγ and as a negative control the 
cells were cultured in medium alone. At the 4 hour and 8 hour time points PD-L1 
increased its intensity of expression on the monocytes which had been cultured in IL-10 
containing medium and IFNγ containing medium. This was expected as there have been 
reports of IL-10 and IFNγ regulating PD-L1 expression (Curiel et al., 2003; Dong et al., 
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2002). Those monocytes cultured in malignant ascites supernatant also showed this 
upregulation in PD-L1 intensity however this did not occur when monocytes were 
cultured in benign supernatant. This could be due to the differences observed in IL-10 
concentrations between malignant and benign supernatant as IFNγ expressed at low 
levels in both cases. 
 
At the time of carrying out this experiment it was known that IL-10 concentrations were 
higher in malignant compared to borderline cases and it was a good candidate to target in 
a pilot functional assay. Due to the limiting supplies of each patient supernatant and time 
restrictions with the project funding only one experiment was carried out. When T cells 
were cultured in 40% supernatant their proliferation was suppressed (Figure 3.13), those 
supernatants with high IL-10 suppressed more than the lower IL-10 supernatants. In 
addition, the presence of a blocking IL-10 antibody partially restored proliferation. 
Following this experiment the TGFβ concentrations were measured and also showed a 
higher level in malignant cases. Future work on this project should focus on repeats of 
IL-10 blocking and include TGFβ blocking as well as a combination of both. The 
experiments should use supernatants from the same patients to allow comparisons of each 
cytokine’s contribution to the observed suppression. This will require collection and 
storage of larger volumes of patient supernatant than has previously occurred during this 
project of equal numbers of malignant and borderline/benign cases. The results of this 
pilot experiment combined with the luminex data would suggest that IL-10 and TGFβ 
contribute in part to the suppression observed when T cells are cultured in ascitic 
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supernatant, and therefore contribute to the overall suppressive tumour microenvironment 
in vivo. 
 
 
3.3.3. Tumour Mass 
Initial attempts to study primary ovarian cancer tumour cells were based on isolation of 
epcam positive cells from ascites. The separation of these cells was often not high purity 
and the lifespan of the isolated cells in culture wasn’t long enough to generate sufficient 
cell numbers for phenotyping and functional experiments. As such PD-L1 expression was 
measured at the mRNA level using frozen tumour sections. PD-L1 expression was shown 
to be higher than normal ovary in borderline, serous and endometrioid cases. Clear cell 
carcinomas showed little PD-L1 expression and is comparable to the normal ovary. The 
normal ovary itself expresses PD-L1 and could be due to the immune privileged nature of 
the organ, however this expression increases during tumorigenesis. Cell lines also proved 
a valuable surrogate for the lack of primary tumour cells and these were also phenotyped 
for PD-L1 using flow cytometry. Similarly to the real time PCR data, clear cell 
carcinoma express little or no PD-L1 even in the presence of IFNγ. Serous cases do 
express PD-L1 constitutively, and increase further in the presence of PD-L1. Based on 
PD-L1 expression alone, it was decided that serous cancer cell lines may be a good 
alternative to primary ovarian cancer cells in subsequent functional experiments both in 
this chapter and the following chapter. As we are investigating the role of the PD-1 
pathway in ovarian cancer, the serous cell lines show a similar expression of the ligand as 
the primary serous cases and offer the best possible alternative to the primary tumour cell.  
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As a possible mechanism of the upregulation of PD-1 and PD-L1 observed on ascitic T 
cells and antigen presenting cells respectively, ovarian cancer cells lines were co-cultured 
with peripheral blood T cells and monocytes from healthy patients. We hypothesised that 
cell surface molecules or soluble factors released by the tumour cell might be the cause of 
the upregulation observed in vivo. OVCAR-3 cells failed to upregulate PD-L1 on 
monocytes over a 48 hour period. Similarly OVCAR-3 and SKOV-3 cells failed to 
upregulate PD-1 on T cells compared to the control HEK cells and unstimulated T cells 
cultured alone. In this in vitro model of tumour cell/T cell interaction there appears to be 
no evidence to suggest the tumour cell is responsible for the upregultation of PD-1 
pathway molecules observed in vivo. It is more likely that cytokines present in the tumour 
environment are responsible for this upregulation as seen when monocytes are cultured in 
ascitic supernatant. 
 
 3.3.4. Conclusion 
In conclusion this chapter has shown the level of PD-L1 on antigen presenting cells from 
ovarian cancer patients strongly correlates with malignancy and is a likely method of 
immunosuppression used by the tumour to survive and grow. Furthermore extensive 
analysis of the cytokine content reveals that there is a high level of immunosuppressive 
and pro-angiogenic cytokines associated with the tumour microenvironment. Overall this 
combination of suppressive cell surface molecules and soluble factors leads to failure of 
the host immune system to eradicate the tumour. As such this chapter has highlighted an 
alternative prognostic marker and possible targets for ovarian cancer therapy. 
 118 
 
4. PD-1 KDEL: A METHOD FOR DOWNREGULATING PD-1 LIGAND 
EXPRESSION 
4.1. Introduction 
The introduction of this thesis has dealt with this subject in great detail, discussing the 
importance of the B7 family of costimulation molecules and their importance in 
activation of naïve T cells. However, there are further molecules involved in the 
maintenance and conclusion of effector/memory T cell responses which are necessary to 
maintain peripheral tolerance and immune system homeostasis (Yamada et al., 2002). 
The PD-1 pathway is one such negative regulatory pathway and as such has presented 
itself as a possible therapeutic target for diseases whose progression is aided by 
suppressing the immune system; one such example would be cancer. 
 
PD-1 is expressed on activated T and B lymphocytes. It is a 55-60 kDa transmembrane 
monomeric protein which contains negative signalling motifs on its intracellular tail 
(ITIM and ITISM motifs). As such it has an inhibitory effect on T cells when ligated by 
its ligands PD-L1 and PD-L2 (Latchman et al., 2001; Shinohara et al., 1994). 
PD-L1 shows a broad expression pattern, which includes myeloid cells, endothelial cells 
as well as cancer cells. It can be upregulated in response to IFNγ (Dong et al., 2002). In 
comparison, PD-L2 is much more restricted in its expression as it is mainly found on 
dendritic cells and macrophages (Latchman et al., 2001). 
 
The PD-1 pathway is known to be involved in the maintenance of tolerance by playing a 
role in both central and peripheral tolerance. PD-1
-/- 
mice develop severe autoimmunity 
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and lymphoproliferative disorders (Nishimura et al., 1999).  Due to this immune 
suppressive function, the pathway has been exploited by many cancer types as a 
mechanism of immune evasion. Many studies have shown that the PD-1 pathway could 
be a potential target for cancer therapy (Dunn et al., 2002). 
 
4.1.1. The PD-1 pathway in Ovarian Cancer 
Few studies have actually been carried out on the PD-1 pathway in ovarian cancer, 
however there are a few important papers which have demonstrated that PD-1 or its 
ligands have an involvement. Hamanishi et al. have shown that PD-L1 expression on 
tumours strongly correlates with prognosis and that PD-L1 expression negatively 
correlates with CD8 T cell infiltration into the tumour (Hamanishi et al., 2007). 
 
There is also evidence of PD-L1 involvement in myeloid derived suppressor cell 
mediated T cell suppression in ovarian cancer. PD-L1 signalling in MDSCs correlated 
with tumour growth and survival in mouse models of ovarian cancer (Liu et al., 2008).  
 
4.1.2. Aims 
The use of KDEL fusion proteins has already been demonstrated in Prof. Andrew 
George’s laboratory in order to prolong allograft survival using a CTLA-4 KDEL 
construct (Tan et al., 2005). The fusion of a receptor molecule to the KDEL sequence 
retains the receptor in the endoplasmic reticulum where it can bind its ligand preventing it 
from reaching the cell surface. This chapter attempts to produce a PD-1 KDEL construct 
which is capable of knocking down PD-L1 on the surface of ovarian cancer cell lines for 
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use in functional studies exploring the role of PD-L1 in suppression of anti-tumour 
immune responses in human epithelial ovarian cancer. 
 
The aims of this chapter were as follows: 
1. Construction of a PD-1 KDEL fusion protein 
2. Demonstrate the function of the PD-1 KDEL construct in knocking down PD-L1 
expression on ovarian cancer cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
 
4.2. Results 
4.2.1. Cloning PD-1 KDEL 
The extracellular domain of PD-1 was to be cloned from activated human T cells. T cells 
were isolated from human peripheral blood (as described in 2.2.8.) and stimulated with 
anti CD3/CD28 beads. PD-1 expression was analysed at 24 hour intervals for 96 hours by 
flow cytometry, the results are shown in Figure 4.1A. PD-1 expression can be detected at 
low levels at 24 hours before increasing to its highest level of 65% compared to an 
isotype control, at 96 hours. Messenger RNA was then extracted from 96 hour stimulated 
T cells, converted to cDNA and used to amplify the extracellular domain of PD-1 by 
PCR. The PCR product was run on an agarose gel and is shown in Figure 4.1B as a ~500 
bp band. A second band is also present and both were extracted, as the smaller of the two 
bands was the only band to ligate into the plasmid and was sequenced correctly it was not 
decided to persue the identity of the larger band further. 
 
The band corresponding to the extracellular domain of PD-1 was ligated into a 
pCMV/myc/ER plasmid (Figure 4.2) and transformed into bacteria. Colonies were 
chosen and DNA extracted and digested with Xho I and Not I to check for the insert. 
DNA from colonies containing the insert were chosen for large scale growth and DNA 
from the resulting cultures was extracted and digested, the gel of the resulting digest is 
shown in Figure 4.2 showing two bands, the larger (5 kb) corresponding to the plasmid 
and the smaller band (~500 bp) corresponding to the inserted extracellular domain of PD-
1. The PD-1 KDEL construct was then sequenced to ensure there were no mutations and 
the insert was in frame with the plasmid sequence. 
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Figure 4.1: Cloning extracellular domain 
of human PD-1. A) flow cytometric 
analysis of PD-1 expression on CD3/CD28 
stimulated total human T cells over a 96 
hour time course. PD-1 expression (green) 
is compared to isotype control (red). B) 
agarose gel showing purified PCR product 
of cDNA extracted from 96 hour 
stimulated T cells using primers specific to 
extracellular domain of PD-1. Two bands 
are observed at around 500 bp 
 
500bp 
400bp 
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Figure 4.2: Restriction enzyme digestion of PD-1 KDEL construct. PD-1 KDEL was 
extracted from bacteria and digested with Xho I and Not I. The resulting products were 
run on an agarose gel (part A). The gel shows a product around 500 bp and a larger band 
at 5 kb. Part B shows the amino acid sequence following nucleotide sequencing of the 
construct. The sequence shows the extracellular domain of PD-1 (purple) in frame with 
the KDEL sequence (yellow). There is a myc epitope (blue) between the PD-1 and 
KDEL for detection purposes. The signal sequence (red) used was part of the pCMV/ER 
vector. Highlighted in the PD-1 extracellular domain are 3 cysteine (yellow) which are 
important later on in Chapter 4. 
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To check whether the PD-1 KDEL construct was producing a protein product, PD-1 
KDEL was used to transfect a D17 cell line. Mock transfected and PD-1 KDEL 
transfected D17 cell lines were incubated for 48 hours to allow protein expression and 
were then lysed and run on SDS PAGE. The Western blot on which the lysates were run 
were then probed using an anti-myc antibody, the resulting Western blot is shown in 
Figure 4.3. The blot shows a band at around 30 kDa in the PD-1 KDEL transfected cells 
which is not present in the mock transfected lysate. 
 
In order to check the function of the PD-1 KDEL construct, a cell lines expressing PD-L1 
was required. A human corneal endothelial cell (HCEC) line was in use in the laboratory 
for other studies and was screened for PD-L1 expression. HCEC were found to express 
PD-L1 following IFNγ stimulation and could therefore be used to check the function of 
PD-1 KDEL (Figure 4.4). 
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 37.1 kDa 
PD-1 KDEL Mock 
Transfected D17 cells 
Figure 4.3: Western blot of transfected D17 cells. D17 cells were transfected with PD-1 
KDEL or a mock pCMV/myc/ER vector. Lysates were run on a reducing 10% SDS PAGE 
and then probed using an anti-myc antibody. A band of around 30 kDa is present in the 
PD-1 KDEL transfected cells but is absent in mock transfected cells. Representative of 
multiple experiments 
 
25.9 kDa 
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PD-L1 
 
 
isotype 
PD-L1 FITC 
Figure 4.4: PD-L1 expression of 
Human Corneal Endothelial 
Cells (HCEC). HCEC were 
stimulated with IFNγ for 48 
hours. PD-L1 expression was then 
analysed by flow cytometry. This 
result was repeated multiple times 
throught the project. 
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HCEC were then transfected with mock and PD-1 KDEL constructs and transfectants 
were selected for using G418 as the transfection efficiency of the Lipofectin method on 
HCEC was low (around 30%). Selected HCEC were then checked for PD-1 KDEL 
expression by Western blot, the blot is shown in Figure 4.5A and shows approximate 30 
kDa band in the PD-1 KDEL transfected cell lysate. The function of the PD-1 KDEL 
contruct was analysed by flow cytometry to detect PD-L1 on mock and PD-1 KDEL 
transfected cells. Figure 4.5B shows mock transfected HCEC express PD-L1 with IFNγ 
stimulation whereas PD-1 KDEL transfected HCEC cannot upregulate PD-L1. 
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PD-1 KDEL Mock 
Transfected HCEC cells 
PD-L1 
 
 
isotype 
PD-L1 FITC 
PD-1 KDEL 
Transfected 
Mock 
Transfected 
A 
B Figure 4.5: PD-1 KDEL transfection 
of HCEC. A) Western blot of PD-1 
KDEL transfected HCEC and mock 
transfected HCEC using anti PD-1 
antibody. The blot shows a band at 
around ~30kDa in the PD-1 KDEL 
transfected lane but not in the mock. B) 
Flow cytometric analysis of PD-1 
KDEL and mock transfected cells 
showing PD-L1 expression following 
48 hour IFNγ stimulation. Mock 
transfected cells upregulate PD-L1 
whereas PD-1 KDEL transfected cells 
cannot. This result was not repeated. 
 
 
37 kDa 
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4.2.2. The Use of PD-1 KDEL to alter PD-L1 expression on Ovarian Cancer Cell 
lines 
PD-1 KDEL was used as a method to down regulate expression of PD-L1 on ovarian 
cancer cell lines, in particular OVCAR-3 and SKOV-3. Both cell lines express PD-L1 
(Figure 3.17.). Firstly transfection efficiency was optimised for OVCAR-3 cells using a 
nucleofection technique. The manufacturer (Lonza, Cologne, Germany) had suggested 3 
different settings (these were pre-programmed settings supplied by the company, no 
further detail is known other than the code chosen on the machine) which could be used 
for OVCAR-3 and these were tested along with one suggested setting for SKOV-3 cells. 
 
Once high transfection efficiency with a GFP containing plasmid was achieved, (Figure 
4.7) optimal settings were used in future experiments for transfection of SKOV-3 and 
OVCAR-3 (V-05 and T-16 respectively). SKOV-3 cells were then transfected with PD-1 
KDEL and mock plasmids and incubated for 48 hours. PD-L1 expression was measured 
by flow cytometry and the results are shown in Figure 4.8. 
 
PD-1 KDEL transfected SKOV-3 cells show similar levels of PD-1 expression as mock 
transfected (~80%) (Figure 4.8A). Figure 4.8 B shows a Western blot probed with anti-
PD-1 and anti-β actin antibody on lysates from mock and PD-1 KDEL transfected 
SKOV-3 cells. The blot shows a β actin band in both lanes and a ~30 kDa band in the 
PD-1 KDEL transfected cells which is absent in the mock. Part C shows transfection 
efficiency of SKOV-3 cells using this nucleofection technique (>80%) as calculated by 
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transfection with a GFP containing construct (Lonza, Cologne) and subsequent flow 
cytometric analysis compared to untransfected SKOV-3. 
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Figure 4.7: Optimisation of OVCAR-3 and 
SKOV-3 nucleofection. A, B and C show 
OVCAR-3 nucleofection with GFP under 3 
conditions (T-16, O-17 and A-26 respectively). T-
16 was chosen as the optimal setting, achieving 
>80% transfection efficiency. D shows SKOV-3 
nucleofection with GFP under the suggested 
condition (V-05), this shows a high transfection 
efficiency of >80%. Once optimal settings had 
been established these transfections were repeated 
multiple times throughout the rest of the project. 
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Figure 4.8: PD-1 KDEL transfection of SKOV-3 cells. A) shows PD-L1 
expression measured by flow cytometry of mock transfected vs. PD-1 KDEL 
transfected SKOV-3 cells. Cells transfected with both constructs show PD-L1 
expression. The PD-1 KDEL construct does not result in the expected 
downregulation of PD-L1 B) shows Western blot of mock transfected and PD-1 
KDEL transfected SKOV-3 cells probing with an anti-PD-1 antibody and an anti-β 
actin antibody. The blot shows a band at the expected β actin molecular weight in 
both lanes and a ~30 kDa band in the PD-1 KDEL transfected lane C) shows green 
flourescence of GFP transfected cells vs. untransfected cells showing 87% 
transfection efficiency suggesting that the transfection efficiency is not the limiting 
factor in this experiment. This transfection was repeated once more. 
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The transfection of PD-1 KDEL into SKOV-3 cells did not result in the expected 
reduction of cell surface PD-L1, one reason for this may be that the turnover of PD-L1 on 
the surface of the ovarian cancer cell lines was too slow for a knock down to appear after 
48 hours. To address this PD-1 KDEL transfected SKOV-3 and OVCAR-3 cells were 
selected with G418 for around 2 weeks to allow enough time for degradation of existing 
PD-L1 on the cell surface. Flow cytometry for PD-L1 on SKOV-3 and OVCAR-3 
selected lines is shown in Figure 4.9. As in Figure 4.8, transfection with PD-1 KDEL 
makes no difference to PD-L1 compared to the mock transfection. To ensure that the 
selected PD-1 KDEL transfected lines were still expressing the PD-1 KDEL protein a 
Western blot was carried out on the lysates of each of the cell lines. The blots are shown 
in Figure 4.10 and the reducing gel shows a band at ~30 kDa in the lanes of PD-1 KDEL 
transfected lines. Interestingly, the non reducing blot shows an additional band at around 
64 kDa which is present in the PD-1 KDEL lanes but not in the mock (this will be 
discussed further below). Therefore we can conclude that the reason we do not observe a 
reduction in PD-L1 is not due to the stability of existing surface PD-L1. 
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Figure 4.9: PD-L1 expression on stably transfected OVCAR-3 and SKOV-3 cell lines. 
OVCAR-3 and SKOV-3 were transfected with a mock or PD-1 KDEL construct. 
Transfectants were selected with G418 for 2 weeks to allow existing surface PD-L1 time to 
degrade. Flow cytometric analysis was carried out to show PD-L1 expression. Following the 
extended incubation time, both SKOV-3 and OVCAR-3 PD-1 KDEL transfected cell lines 
show similar levels of PD-L1 as the mock equivalents. 
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Figure 4.10: Western blot of stably transfected OVCAR-3 and SKOV-3 cell lines. Top 
panel shows a reducing Western blot using an anti-PD-1 antibody to probe lysates from PD-1 
KDEL and mock transfected cell lines. Bottom panel shows non reducing blot of the same 
transfected cell lines. A β actin antibody was used as a positive control. The non reducing blot 
shows a band at 64kDa in the PD-1 KDEL transfected cells which is not present in the reduced 
blot. This is representative of 2 experiments. 
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The Western blot results from Figure 4.10 raised the possibility that PD-1 KDEL could 
be dimerising. This offered an alternative explanation as to why we are not seeing the 
expected downregulation of PD-L1 following PD-1 KDEL transfection, as dimerisation 
of the normally monomeric PD-1 molecule could interfere with the PD-L1 binding 
surface. This will be explained fully in the discussion following these results, but briefly, 
it was decided that cysteine 60 of the extracellular domain of PD-1 would be mutated to a 
serine residue in order to stop this dimerisation. Once the mutation had been introduced 
and confirmed by sequencing, the mutated construct (referred to from here on as 
mKDEL) was transfected into OVCAR-3 cells and PD-L1 expression was measured by 
flow cytometry after 48 hours. The results are shown in Figure 4.11 and again show that 
PD-L1 expression is similar between the mock transfected cells and the mKDEL 
transfected cells. 
 
In a similar manner to those OVCAR-3 cells transfected with PD-1 KDEL, it was thought 
that longer time periods were needed to be examined in order to allow natural turnover of 
existing PD-L1 on the cell surface. As a result mKDEL transfected OVCAR-3 cells were 
selected with G418 for >10 days and PD-L1 was re-analysed by flow cytometry. Figure 
4.12A shows the flow cytometry results of selected mock and mKDEL transfected 
OVCAR-3 and again show similar levels of PD-L1. Part B shows a reduced Western blot 
of the selected cell lines as well as a PD-1 KDEL transfected cell line probed with anti 
PD-1 antibody, confirming the expression of a PD-1 KDEL construct at around 30 kDa in 
both the PD-1 KDEL and mKDEL transfected lines. Interestingly, the non reduced 
Western blot in part B shows the 30 kDa band in both the KDEL and mKDEL lanes, as 
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well as an additional band at around 64 kDa in the KDEL lane which is absent in the 
mock and mKDEL lanes. This suggests that the mutation of the Cys 60 residue has 
eliminated dimerisation of the PD-1 KDEL construct. Therefore it can be concluded that 
introduction of the mutation at Cys 60 stops dimerisation of the PD-1 KDEL construct, 
although this inhibition of dimerisation does not lead to the expected reduction of PD-L1 
on the surface of the transfected cells. This is not due to stability of existing PD-L1 as 
this was controlled for using a longer incubation time. 
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Figure 4.11: PD-L1 expression on OVCAR-3 cells transiently transfected with 
mutant PD-1 KDEL (mKDEL). OVCAR-3 cells were transfected with mKDEL or 
control plasmids and PD-L1 expression was measured after 48 hours. Expression of PD-
L1 in both transfections is similar. This is representative of 2 experiments. 
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Figure 4.12: PD-L1 expression following G418 selection on OVCAR-3 cells 
transfected with mutant PD-1 KDEL (mKDEL). OVCAR-3 cells were transfected with 
mKDEL or mock plasmids. Cell lines were grown in G418 containing medium for at least 
10 days to allow turnover of existing PD-L1 on the cell surface. A) PD-L1 expression was 
then measured by flow cytometry and shows similar expression with both mKDEL and 
mock transfections. B) reduced and non reduced Western blots of KDEL, mKDEL and 
mock transfections probed with anti-PD-1 antibody showing ~30 kDa bands in KDEL and 
mKDEL reduced blots corresponding to monomeric PD-1 KDEL. The non reduced blot 
shows a larger 64 kDa band in the KDEL lane but not the mKDEL lane suggesting the 
mutation in mKDEL has eliminated dimerisation of the construct. This is representative of 
2 experiments. 
 
mKDEL Mock 
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In order to investigate whether or not PD-1 KDEL and mKDEL were being expressed in 
a functional form (folded correctly and able to bind its ligands and a monoclonal anti-PD-
1 antibody) and are present in the endoplasmic reticulum (ER), confocal microscopy on 
transfected OVCAR-3 cells was carried out. Transfected cells were stained with both an 
ER tracker (Invitrogen, UK) and an anti-PD-1 alexa fluor 647 antibody (Ebioscience, 
UK) after 24 hours. Each fluorescent marker was excited and detected independently and 
the images are shown in Figure 4.13. Figure 4.13 parts A, B and C show ER staining 
(green), parts D, E, and F show PD-1 staining (red) and parts G, H and I show a merge of 
both images. Both PD-1 KDEL and mKDEL transfected cells show PD-1 expression (F 
and E respectively) which overlaps with ER staining (I and H respectively) as shown by 
yellow areas suggesting localisation of KDEL and mKDEL constructs in the ER. 
Interestingly, mock transfected OVCAR-3 cells show PD-1 expression (part D), which 
suggested that wild type OVCAR-3 can also express PD-1 as well as PD-L1. This was 
later confirmed by flow cytometry, staining PD-1 on the surface of OVCAR-3 cells 
(Figure 4.14 A). This experiment cannot be used to conclude that there is PD-1 KDEL 
localisation in the ER as we cannot distinguish between endogenous PD-1 and transfected 
PD-1 KDEL or mKDEL. 
 
As a result of wild type OVCAR-3 expressing PD-1, it was decided that intracellular flow 
cytometry should be used to demonstrate the PD-1 KDEL construct was being expressed 
inside OVCAR-3 cells. Using this method we could compare endogenous levels of PD-1 
with the levels of intracellular PD-1 following PD-1 KDEL transfection. The results of 
this are shown in Figure 4.14 B. The flow cytometry profiles show that when transfected 
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with PD-1 KDEL the percentage of OVCAR-3 cells expressing PD-1 rises to 66% as 
compared to the baseline expression in mock transfected cells of 28%. This suggests that 
PD-1 KDEL is being expressed in a functional form as there is an increase on 
endogenous PD-1 levels being detected by a monoclonal anti-PD-1 antibody which 
would recognise the folded form of PD-1. This experiment does not however confirm the 
localisation of PD-1 KDEL in the ER. 
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KDEL 
mKDEL 
PD-1 ER Merge 
Figure 4.13: Confocal microscopy of PD-1 KDEL, mKDEL and mock transfected 
OVCAR-3 cells. OVCAR-3 cells were transfected with PD-1 KDEL, mKDEL and mock 
constructs and stained with an ER tracking dye (green) and an anti-PD-1 alexa fluor 647 
antibody (red) following 24 hour incubation. Each fluorescent stain was excited 
independently of one another and then merged (final column) to show any colocalisation of 
the two stains. Overlapping stains appear as yellow in the final merged column (mock and 
mKDEL are shown at 40x magnification, PD-1 KDEL is shown at 100x magnification). 
These pictures represent 10 randomly chosen positions on each slide. 
A 
B 
C 
D 
E 
F 
G 
H 
I 
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Figure 4.14: PD-1 expression on OVCAR-3 cells. A) shows surface PD-1 
expression on wild type OVCAR-3 cells showing a low yet detectable level of 
PD-1 on the cell surface B) shows intracellular PD-1 expression on OVCAR-3 
cells following transfection with mock or PD-1 KDEL constructs after 24 hours. 
Endogenous PD-1 is detectable in the mock transfected cells and this is then 
increased by ~40% following PD-1 KDEL transfection. This is representative of 
2 experiments. 
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As an alternative method to use confocal microscopy to determine the co-localisation of 
the PD-1 KDEL construct and the ER, an anti-myc antibody was used. A myc tag is 
present in the construct between the extracellular domain of PD-1 and the KDEL 
sequence, this means it will detect PD-1 KDEL/mKDEL and not the endogenous PD-1 
and allow co-localisation with the ER to be measured. OVCAR-3 cells were transfected 
with PD-1 KDEL or mKDEL and stained for the ER and anti-myc antibody. 
Untransfected OVCAR-3 cells were used as a negative control. Parts A, B and C of 
Figure 4.15 show the ER staining for all conditions of OVCAR-3 cells showing a clear 
linear staining pattern characteristic of the ER. Parts D, E and F show anti-myc staining. 
Part E and F correspond to PD-1 KDEL and mKDEL transfected OVCAR-3 respectively 
and show clear red staining in a similar pattern to the ER staining. Part D is untransfected 
cells and shows no staining. Parts G, H, and I show a overlay of the ER and anti-myc 
stains. The PD-1 KDEL (H) overlay shows clear yellow staining corresponding to a 
colocalisation of anti-myc and ER. Overlay analysis by the confocal software gave an 
overlap efficiency of 71%. Similarly the mKDEL (I) overlay shows yellow staining and 
the computer analysis stated that there was an overlap efficiency of 84%. This experiment 
suggests that PD-1 KDEL and mKDEL are expressed and localized in the ER. The 
cellular location of these proteins is as expected and is not a reason for the fact that they 
are not able to downregulate PD-L1 in OVCAR-3 cells. 
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Figure 4.15: Confocal microscopy of PD-1 KDEL, mKDEL transfected and 
untransfected OVCAR-3 cells. OVCAR-3 cells were transfected with PD-1 
KDEL or mKDEL constructs or untransfected and stained with an ER tracking 
dye (green) and an anti-myc alexa fluor 555 antibody (red) following 24 hour 
incubation. Each fluorescent stain was excited independently of one another and 
then merged (final column) to show any colocalisation of the two stains. 
Overlapping stains appear as yellow in the final merged column (all pictures at 
100x magnification). These pictures represent 10 randomly chosen positions on 
each slide. 
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4.2.3. Investigating the effect of blocking PD-1 on tumour cell and T cell interactions 
Following the unsuccessful approach of using PD-1 KDEL constructs to knock down PD-
L1 expression on the surface of ovarian cancer cell lines, an alternative method of 
blocking the pathway was required. The antibody used to stain T cells for PD-1 in 
previous Figures also had a reported blocking activity and so it was decided that this 
could be used to block the PD-1 pathway and carry out the intended functional 
experiments. To test the blocking nature of the antibody, a mixed lymphocyte reaction 
(MLR) was optimized using dendritic cells and T cells from two different donors. CD14+ 
cells were isolated from peripheral blood and differentiated into dendritic cells (DC) by 
culturing in media containing IL-4 and GM-CSF for 6 days. DCs were either used as 
immature, or matured  using IL-1β and TNFα. These DCs were cultured with T cells in a 
1:10 ratio for at least 5 days and 7 days with or without the anti PD-1 blocking antibody. 
The results are shown in Figure 4.16.  
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Figure 4.16: Testing the anti-PD-1 blocking antibody. T cells and 
dendritic cells from different donors were cultured in a 10:1 ratio with 
(dashed lines) or without (solid lines) the blocking antibody. Immature (red 
lines) and mature dendritic cells (green lines) were used as stimulators. 
Proliferation was measured on days 5 and 7. mDC are able to stimulate T 
cells more than iDC, in both cases the presence of the PD-1 blocking 
antibody enhances the proliferation of the T cells although to a greater 
extent in the case of iDC. This is representative of 2 experiments. 
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T cells proliferate more in the presence of mature DCs than in the presence of immature 
DCs. In both cases this proliferation can be enhanced in the presence of the blocking 
antibody, with the greater effect occurring with immature DCs. This Figure demonstrates 
the use of this anti-PD-1 as an effective means of blocking the PD-1 pathway and 
enhancing T cell proliferation. In light of this result it was decided that the anti-PD-1 
antibody could be used as an alternative to the PD-1 KDEL construct in the planned 
functional work.  
 
OVCAR-3 cells were cultured with bead stimulated, CFSE labeled T cells for 5 days in 
the presence or absence of a PD-1 blocking antibody. Flow cytometry analysis was used 
to compare the proliferation of T cells in all experimental conditions. The results are 
shown in Figure 4.17. Part B shows unstimulated T cells, showing a lack of CFSE 
dilution compared to part A which shows CD3 CD28 bead stimulated T cells. Part C 
shows T cells in the presence of OVCAR-3 but no antibody. The presence of the 
OVCAR-3 cells suppresses T cell proliferation compared to the stimulated T cells alone 
(part B). However, blocking PD-1 fails to reverse this suppression (part D). 
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Figure 4.17: PD-1 blockade in OVCAR-3/T cell coculture. OVCAR-3 and 
CFSE labelled anti-CD3/CD28 bead stimulated T cells were cultured in the 
presence (C) or absence (D) of PD-1 blocking antibody (1:10 ratio). CD3/CD28 
bead stimulated (A) and unstimulated (B) T cells alone were used as controls with 
stimulated T cells showing a 91% shift to the left corresponding to a dilution of 
CFSE and therefore more proliferation. The presence of the OVCAR-3 cells 
suppresses the T cell proliferation by around 50%, this cannot be reversed by 
addition of anti-PD-1 blocking antibody which shows the same level of 
proliferation as those cells without the antibody. This suggests that blocking PD-1 
may not be of benefit to enhancing T cell proliferation in this experiment. This is 
representative of 2 experiments. 
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4.3. Discussion 
The previous chapter focused on the immune system involvement in human ovarian 
cancer, in particular the PD-1 pathway. The data presented in chapter 3 suggested that 
PD-L1 was a potential target in ovarian cancer as it had correlated with malignancy in its 
expression pattern on antigen presenting cells, tumour cell lines and the tumour mass 
itself. With this in mind it was decided to use a novel method to target and knock down 
PD-L1 expression on cancer cells to use in functional assays to demonstrate the potential 
of targeting PD-L1 in ovarian cancer. The aims of this chapter were to produce a PD-1 
KDEL fusion protein which, when expressed in cancer cells would remain in the ER and 
bind to PD-L1 and prevent its trafficking to the surface. This idea was based on previous 
work in Prof. George’s lab involving CTLA-4 KDEL being transfected into human 
primary dendritic cells and showing its capacity to knock down CD80 and CD86 
expression (Tan et al., 2005). 
 
4.3.1. Cloning and testing PD-1 KDEL 
Cloning of the fusion protein involved the amplification and ligation of the extracellular 
domain of human PD-1 to the KDEL sequence present in the pCMV/ER plasmid 
(Invitrogen). Human T cells were isolated from peripheral blood and stimulated using 
CD3/CD28 beads and analysed for PD-1 expression by flow cytometry over a 96 hour 
time course. PD-1 expression was highest at 96 hours and the mRNA was extracted from 
these T cells and converted to cDNA which was used as the source of PD-1 for the 
amplification of the extracellular domain (Figure 4.1). Following successful amplification 
and ligation into the pCMV/ER plasmid the construct was sequenced. Sequencing 
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confirmed that the extracellular domain of PD-1 was fused correctly in frame with the 
KDEL sequence (Figure 4.2). Confirmation of the ability of the construct to produce a 
protein product came following a transfection into D17 cells and subsequent Western blot 
probing for anti-myc (fused in between PD-1 and KDEL) (Figure 4.3). As the construct 
was correct in sequence and was producing a protein product it was decided to test the 
construct on a cell line which expressed PD-L1 and was easy to transfect. Human corneal 
endothelial cells (HCEC) were being used in the laboratory at the time and so they were 
screened as a source of PD-L1. HCEC expressed PD-L1 at a level high enough to observe 
a knock down. This required IFNγ stimulation. HCEC were transfected with lipofectin 
although only to a moderate efficiency of around 30% and so it was decided to select for 
those HCEC which retained expression of the plasmid using G418 containing medium. 
Following 10 days of selection, HCEC were stimulated with IFNγ and screened for PD-
L1 expression using flow cytometry. Figure 4.5 shows the results of the transfection of 
PD-1 KDEL into HCEC and shows a reduction of PD-L1 on KDEL transfected cells 
compared to mock transfected cells. This represented the only evidence that PD-1 KDEL 
was functional and could knock down its target.  
 
Following successful cloning and expression of PD-1 KDEL the construct was to be used 
in its target cells. In chapter 3, a number of common ovarian cancer cell lines were 
screened for PD-L1 expression, the data shows a correlation of PD-L1 with the serous 
histotype of ovarian cancer. Two serous lines were chosen to be used in the next part of 
this project which showed high expression of PD-L1, OVCAR-3 and SKOV-3. At this 
time we had gained access to a nucleofection technique of transfection into cell lines. The 
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Amaxa technology had already been optimized for SKOV-3 cells and on personal contact 
with the company (Lonza, Cologne), 3 settings were suggested on the machine for use 
with OVCAR-3 cells. Nucleofection is an electroporation technique which can transfect 
DNA directly into the nucleus of cells and therefore achieve a more successful 
transfection. Of the three settings suggested by the company for nucleofection of 
OVCAR-3, one was chosen which gave the highest transfection efficiency as judged by 
deconvolution microscopy of GFP transfected OVCAR-3 cells. Both OVCAR-3 and 
SKOV-3 could routinely be transfected with efficiencies of 80% and above. PD-1 KDEL 
was transfected into these cell lines and following a 48 hour incubation the cells were 
analysed for PD-L1 using flow cytometry. Unexpectedly, the KDEL transfected cell lines 
still showed similar levels of PD-L1 as the mock transfected unlike the HCEC 
transfection. It was hypothesized that turnover of existing PD-L1 on the cell surface 
could be a factor. PD-1 KDEL can block the trafficking of newly synthesized PD-L1 to 
the cell surface but it cannot remove PD-L1 which already exists. As the HCEC were 
selected for 10 days we thought this was sufficient time for existing surface PD-L1 to be 
degraded. SKOV-3 and OVCAR-3 were transfected with PD-1 KDEL and grown in 
G418 selection media for at least 10 days. Flow cytometry was then used to analyse 
surface expression of PD-L1 (Figure 4.9). Again the same result was seen for both cell 
lines with PD-1 KDEL unable to knock down PD-L1 on the cell surface. Western blots 
were carried out on the cell lines to ensure that they still expressed the protein and 
confirmed the presence of the PD-1 KDEL in the selected lines (Figure 4.10). 
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During the process of Western blotting the selected cell lines, both reduced and non 
reduced gels were ran in parallel. We noticed that in the non reduced blots we could 
detect a larger band suggesting the presence of dimeric PD-1 (Figure 4.10). It is well 
established in the literature that PD-1 exists in a monomeric form, however the amino 
acid sequence of the extracellular domain showed the presence of an unpaired cysteine 
residue. Cysteine residues have the ability to form disulphide bridges with each other. 
There are two other cysteine residues in the extracellular domain of PD-1 and both are 
highly conserved amongst species. These two cysteines are responsible for an internal 
disulphide bond. The third cysteine was assumed, by us, to be cryptic and therefore 
hidden from forming inter chain disulphide bonds and oligomeric PD-1. However when 
reading two papers involving the crystallization of the extracellular domain of human 
PD-1 for use in structural experiments, we noticed that the authors in both papers had 
mutated the unpaired cysteine residue at position 60 (see Figure 1.3)  (Lazar-Molnar et 
al., 2008; Zhang et al., 2004). The reasons for this were not explained, although we 
assumed that when cloning the extracellular portion of PD-1 the Cys60 residue became 
exposed and was able to form dimers. It was hypothesized that the PD-1 KDEL construct 
was forming a dimer and perhaps shielding important binding surfaces involved in the 
PD-1-PD-L1 interaction. It was decided that the cys 60 residue should be mutated to a 
serine residue as in the case of the two cited papers. This was successfully achieved and 
sequenced (data not shown), and the mutant KDEL (mKDEL) construct was used in 
subsequent experiments. Following transfection of OVCAR-3 with mKDEL, flow 
cytometry revealed that there was no knock down of PD-L1 compared to the mock. This 
was repeated with selection to control for slow surface turnover of PD-L1 but again there 
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was no knock down. Western blot data showed that mKDEL produced a protein product 
and a non reducing gel showed the removal of the heavier dimeric band suggesting that 
the mutation was successful. We have no direct evidence to suggest that the mutation of 
this cys 60 residue does not interfere with PD-L1 binding, however from the crystal 
structure of PD-1 shown in the Lazar-Molner et al. paper, the cys 60 is not located at the 
ligand binding region of the PD-1 molecule. 
 
At this point there is evidence of PD-1 KDEL having correct sequence in frame, the 
construct can express a protein product, and there is a control for dimerisation which is 
also unsuccessful at knocking down PD-L1. It was hypothesized that although protein 
was being detected on a Western blot, perhaps the PD-1 KDEL was not being retained in 
the ER. To explore this, confocal microscopy was used with an ER tracker and an anti 
PD-1 antibody to try to colocalise the ER and the KDEL construct. Confocal microscopy 
is a very high resolution technique which can produce clear images at 100x 
magnification. The software on the microscope is also able to overlay two fluorescent 
stains and calculate a co-localisation efficiency.  
 
OVCAR-3 cells were transfected with PD-1 KDEL and mKDEL stained for ER and anti-
myc in order to visualize the myc tag present in the construct via confocal microscopy. 
The results suggested that in both cases the KDEL constructs were being retained 
correctly in the ER as determined by the overlap of the fluorescent markers. It can be 
concluded that the reason for the lack of function of KDEL constructs in OVCAR-3 cells 
is not a result of improper retention in the ER. 
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As a precursor to staining OVCAR-3 cells with an anti-myc antibody, transfectants were 
stained with an anti-PD-1 antibody. This was expected to give similar results to the anti-
myc staining however in this case the mock transfected cells showed positive staining for 
PD-1. Flow cytometry analysis for PD-1 also confirmed this expression of PD-1 on the 
surface of OVCAR-3 cells. This is a different situation from the previous use of KDEL 
constructs, such as the use of CTLA-4 KDEL in dendritic cells as the target cells in this 
case express both the receptor and the target ligand. In the case of DCs, CD80 and CD86 
is the target for CTLA-4 KDEL, however DCs do not express CTLA-4 or CD28. HCEC 
also express PD-L1 and do not express PD-1, and PD-1 KDEL has been successfully 
used in these cells. OVCAR-3 cells on the other hand do express PD-1 in addition to PD-
L1. We hypothesise that the presence of endogenous PD-1 may be having a competitive 
inhibitory effect on the function of PD-1 KDEL.  As PD-1 KDEL would work by binding 
PD-L1 in the ER, there is just as much likelihood of endogenous PD-1 binding to newly 
synthesized PD-L1. PD-L1 bound to PD-1 KDEL would be retained in the ER, however 
endogenous PD-1 would not be and any complex formed with PD-L1 would be assumed 
to enter the normal trafficking pathway. We propose that for KDEL fusion protein 
technology to work, the target cell must not express the binding partner of the target 
protein. 
 
In order to test this hypothesis we would plan future experiments involving transfection 
of PD-1 negative cells with PD-1 KDEL. We would propose that transfection of any PD-
1
-
 PD-L1
+
 cell line such as HCEC or THP-1 cells with PD-1 KDEL should result in a 
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knock down of PD-L1 on the surface. If we then co-transfect with a PD-1 Ig construct 
this would introduce PD-1 into the ER which would not be retained and mimic 
endogenous PD-1, we propose that introduction of a competitor of PD-1 KDEL should 
result in an increase of PD-L1 on the cell surface.  During the project a PD-1 Ig fusion 
protein construct was cloned and production of a PD-1 Ig fusion protein was attempted 
although following low yields of the protein in the cell culture supernatant the production 
and purification of the protein was abandoned. However, despite low secretion of the 
protein in the media of the cell culture the protein was still detectable inside the 
transfected cells suggesting PD-1 Ig was being produced but it was being secreted poorly. 
This construct could be used to test our hypothesis stated above. 
 
4.3.2.PD-1 KDEL alternatives 
As an alternative to the PD-1 KDEL method, a blocking antibody was used which 
targeted PD-1. There are several documented studies involving the use of a blocking 
antibody against PD-1 or its ligands in order to inhibit the PD-1 pathway in cancer as 
well as other pathologies (Blank et al., 2006; Brown et al., 2003; Curiel et al., 2003). The 
aim of this chapter was to investigate the effect of blocking PD-1 on T cell responses to 
ovarian cancer, and although PD-1 KDEL was unsuccessful, a blocking antibody enabled 
us to carry out the planned in vitro functional experiments. To ensure the antibody did 
function as expected, an MLR was optimized using human DCs and T cells and this 
reaction was incubated with or without the antibody. The presence of the antibody proved 
successful, and enhanced T cell proliferation in response to both immature DCs and 
mature DCs. This was good evidence that the antibody could block the PD-1 pathway and 
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it was used in proliferation assays involving stimulated T cells incubated with OVCAR-3 
cells. OVCAR-3 have the highest level of PD-L1 surface expression out of all ovarian 
cancer cell lines tested and would be a good surrogate model to mimic the interaction of a 
T cell with the cancer cell. The presence of OVCAR-3 inhibited T cell proliferation, 
although the results also suggested that the use of the PD-1 blocking antibody had no 
effect on T cell proliferation. This was unexpected, although it could be hypothesized that 
OVCAR-3 is suppressing T cell proliferation another way. Data from our laboratory 
(unpublished) suggest that serous ovarian cancer cell lines express indoleamine 2,3 
deoxygenase (IDO), an enzyme which catabolises tryptophan and has a negative effect on 
T cell proliferation (Munn et al., 1998). In addition to this, OVCAR-3 have been reported 
to produce high levels of IL-10 which could also contribute to T cell inhibition (Berger et 
al., 2001).  
 
4.3.3. Conclusion 
Overall this chapter set out to construct a PD-1 KDEL fusion protein which could be 
transfected into ovarian cancer cell lines to investigate the effect of the loss of PD-L1 
from the cancer cell on the T cell response against that cancer cell. Although PD-1 KDEL 
was successfully cloned and expressed in a number of cell lines, its function could not be 
demonstrated in the target cells. After exhausting all possibilities to find out why PD-1 
KDEL was not functioning in OVCAR-3 cells, the data suggested that due to the 
presence of endogenous PD-1, the PD-1 KDEL was facing competition to bind its ligand 
and therefore failing to reduce its surface expression. As an alternative a blocking 
antibody against PD-1 was used and demonstrated to work in a standard allogeneic MLR. 
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This antibody was used in OVCAR-3/T cell proliferation assays, but failed to reverse the 
suppression observed when OVCAR-3 cells were co-cultured with T cells. As a result of 
this we hypothesize that the PD-1 pathway is not the major factor causing the suppression 
of T cells in this assay. This may mirror the in vivo scenario, where a number of factors 
probably contribute to the overall suppression of the immune response. From the data 
described in chapter 3, it is clear that a number of factors could contribute to suppression 
such as suppressive cytokines and the PD-1 pathway. In addition our laboratory has 
shown evidence of T reg and IDO involvement in human ovarian cancer (unpublished 
data). This will be discussed in detail in the following chapter. 
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CHAPTER 5: DISCUSSION 
The PD-1 pathway is an inhibitory T cell co-stimulation pathway (Yamada et al., 2002). 
It plays a role in maintaining T cell homeostasis and peripheral tolerance by negatively 
regulating T cell activity (Yamada et al., 2002). Due to this inhibitory nature, the pathway 
is a good candidate to investigate as a target for potential tumour immunotherapies. In 
ovarian cancer specifically, work into the PD-1 pathway is limited, however there are a 
few studies which suggest PD-L1 may be a potential prognostic marker and a possible 
target for tumour therapy (Curiel et al., 2003; Hamanishi et al., 2007). The aim of this 
study was to fully characterise the PD-1 pathway molecule expression on immune cells 
associated with the tumour in ovarian cancer. In addition to this a second results chapter 
dealt with a novel method of blocking the PD-1 pathway in order to try and boost T cell 
responses against the tumour. 
 
Chapter 4 of this thesis looked at a novel method of targeting the ligands of PD-1 and 
knocking down expression of these molecules in target cells. For this study the target cell 
of interest would be the tumour cell, however this technique could be applied to any other 
cell type of interest such as antigen presenting cells. The basis of the PD-1 KDEL 
construct was that PD-1 was fused to a ER retention sequence which, when expressed in 
the target cell would be retained in the ER. The ligands of PD-1 would then be translated 
and modified in the ER where they would bind the PD-1 KDEL protein and be retained 
themselves and prevent trafficking to the cell surface. The PD-1 KDEL construct was 
correctly cloned according to sequence analysis and produced a protein product in 
multiple cell lines. However when PD-1 KDEL was transfected into ovarian cancer cell 
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lines SKOV-3 and OVCAR-3 it failed to achieve the desired downregulation of PD-L1. 
There were a few potential reasons for this lack of function such as a) existing PD-L1 
being stably expressed on the cell surface during the 48 hour incubation time, b) 
dimerisation of the PD-1 KDEL construct leading to prevention of it interaction with PD-
L1, c) improper cell localisation of PD-1 KDEL and failure to produce a correctly folded 
protein. Each of these reasons was addressed. The incubation time following transfection 
of OVCAR-3 cells with PD-1 KDEL was lengthened to around 10 days by using G418 
selection medium to select for transfected cells. This increased incubation time would 
have given existing PD-L1 the chance to be degraded and the PD-1 KDEL construct 
would have prevented further PD-L1 reaching the surface. This was not the case and no 
downregulation of PD-L1 was observed after this incubation time. 
 
When checking the OVCAR-3 lysates for PD-1 KDEL expression following this 10 day 
incubation we noticed a heavier band on the non-reduced Western blot suggesting 
dimerisation of the construct. PD-1 does not normally dimerise, however we checked the 
sequence and found an unpaired cysteine residue in the extracellular domain which is 
presumably hidden in the full PD-1 molecule preventing it from forming a disulphide 
bridge and PD-1 remains as a monomer (see Figure 1.3.). In our case, we had cloned the 
extracellular domain of PD-1 alone and this could mean that the cysteine residue was 
exposed and could be dimerising. Furthermore two papers which had cloned PD-1 
extracellular domain for crystallographic studies had both mutated the unpaired cysteine 
residue. It was decided that the cysteine residue should be mutated to a serine (both 
papers had carried out the same mutation) (Lazar-Molnar et al., 2008; Zhang et al., 2004). 
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Western blot analysis of mutant KDEL (mKDEL) and PD-1 KDEL transfected OVCAR-
3 cells revealed that the introduction of the mutation had removed the heavier band 
observed around 64 kDa on a non reducing gel. However, flow cytometric analysis on 
mKDEL and PD-1 KDEL transfected OVCAR-3 showed similar PD-L1 expression to 
mock transfected cells. Dimerisation had been prevented but this was not the cause of the 
lack of function of PD-1 KDEL. 
 
Finally it was hypothesised that perhaps the PD-1 KDEL construct was not producing a 
correctly folded protein product which was being correctly retained in the ER. Confocal 
microscopy of PD-1 KDEL and mKDEL transfected OVCAR-3 revealed that there was 
indeed co-localisation of the ER and PD-1 KDEL. Using an ER tracker and a monoclonal 
antibody against the myc tag in the construct we were able to show a merging of the two 
fluorochrome tags suggesting both KDEL constructs were resident in the ER. A previous 
experiment to this had used an anti-PD-1 antibody to visualise the KDEL constructs using 
confocal microscopy. This experiment revealed that OVCAR-3 has endogenous PD-1 
expression as the mock transfected construct showed positive staining for PD-1. Cell 
surface and intracellular flow cytometry revealed that wild type OVCAR-3 naturally 
expressed PD-1. Furthermore this experiment confirmed that PD-1 KDEL was correctly 
folded as the antibody used for intracellular staining was monoclonal and recognises a 
conformational epitope. This endogenous expression of PD-1 was unexpected and forms 
the basis of our current working hypothesis as to why PD-1 KDEL constructs do not 
work as expected in OVCAR-3 cells. We suggest that PD-1 KDEL faces competition 
from endogenous PD-1 in the ER to bind to PD-L1. Any PD-L1 that binds endogenous 
 162 
 
PD-1 should reach the cell surface as this is presumably a natural interaction which 
occurs in wild type OVCAR-3. This means that there is less PD-L1 to bind to PD-1 
KDEL and therefore a significant downregulation on the cell surface is not observed.  
 
Previous studies in our lab using KDEL constructs have used cell types which do not 
express both the receptor and the ligand and therefore face no problems from competition 
between the KDEL construct and the natural receptor. CTLA-4 KDEL has been used 
extensively in our lab in dendritic cells to successfully reduce expression of CD80 and 
CD86 (Tan et al., 2005). Dendritic cells do not express CTLA-4 or CD28 and so there is 
no problem of competition. We hypothesise that for a KDEL construct to be successful 
the cell type cannot express the receptor for the ligand. 
 
Chapter 3 of this thesis dealt with the immune system in ovarian cancer. In particular this 
chapter focussed on the PD-1 pathway and the cytokines involved in the tumour 
microenvironment. The most striking result of this chapter was that PD-L1 was highly 
expressed on antigen presenting cells from patients with malignant ovarian cancer. This 
was significantly higher than patients with benign/borderline ovarian cancer which 
showed very low PD-L1 expression. This result was observed in both the blood and the 
ascites of patients and we hypothesise that it is a mechanism of immunosuppression. A 
caveat to these data however is the fact that the sample sizes were low, this is important 
to consider when interpreting the results and will be discussed in the future work section 
below. 
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We have preliminary evidence which suggests that IL-10 may be important in the 
upregulation of PD-L1 on monocytes, and that this elevated PD-L1 is involved, in part, in 
inhibition of T cell proliferation in vitro. The IL-10 dependent upregulation of PD-L1 is 
an observation that has also been shown in patients with HIV and hepatitis B infections 
(Geng et al., 2006; Trabattoni et al., 2003). In both cases there has been a correlation with 
increased IL-10 and PD-L1 expression on dendritic cells, however it remains to be seen 
whether this IL-10 increase results in upregulation of PD-L1 or whether PD-L1 signalling 
results in production of IL-10 by the DC. 
 
A recent study by Kuang and colleagues has shown similar findings to ours by reporting 
PD-L1 upregulation on monocytes associated with cancer. They have shown that in 
human hepatocellular carcinoma, PD-L1 is upregulated on monocytes in an IL-10 
dependent manner. This is consistent with our findings in ovarian cancer. Moreover this 
PD-L1 expression was shown to be functionally significant in inhibiting antitumour 
immune responses. T cells which were cultured in the presence of anti-PD-L1 blocking 
antibody and PD-L1
+
 monocytes caused a significant reduction of hepatoma growth when 
transferred into a human non–obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mouse tumour model. Transfer of T cells which were cultured with PD-L1
+
 
monocytes with a control antibody resulted in progressive tumour growth (Kuang et al., 
2009). 
 
Similar findings to ours have been shown in ovarian cancer concerning PD-L1 expression 
on tumour associated antigen presenting cells. A study by Curiel et al. showed that 
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dendritic cells removed from tumour draining lymph nodes (TDLN) and ascites had high 
expression of PD-L1 compared to control lymph node dendritic cells. These dendritic 
cells can also upregulate PD-L1 in response to recombinant IL-10 and VEGF in vitro. 
The authors also found that blockade of PD-L1 on these cells with an anti-PD-L1 
antibody resulted in increased T cell expression of IFNγ, IL-2 and IL-12 and a 
downregulation of IL-10. Interestingly this result was not reproducible using PD-1 Ig 
fusion protein, and the anti-PD-L1 antibody (clone 5H1) which was used did not block 
the PD-L1/PD-1 interaction (Curiel et al., 2003). This suggests that PD-L1 on antigen 
presenting cells is important in suppressing anti-tumour immune responses however not 
through its interaction with PD-1 on the T cell. This would explain the data in chapter 3 
where blockade of PD-1 using a blocking antibody only results in a small increase in T 
cell proliferation when T cells are cultured with ascitic monocytes from ovarian cancer 
patients. Perhaps the PD-L1 on monocytes suppresses T cells via its interaction with 
CD80 as well as its interaction with PD-1. This would suggest that using an antibody 
against PD-L1 which can block both its interaction with PD-1 and CD80 would be of 
more benefit in cancer treatment than anti-PD-1 antibodies. 
 
The cytokine profile of the ascites revealed a high concentration of pro-angiogenic 
cytokines (VEGF, IL-8) as well as immunosuppressive cytokines (IL-10 and TGF-β). In 
addition to these cytokines being highly expressed, we found low expression of cytokines 
associated with T cell responses (IL-2, IL-4, IFNγ, IL-17, IL-12). Overall these data 
suggest that the tumour microenvironment is a very hostile environment for anti-tumour 
immune responses and this may contribute to the growth and progression of the tumour. 
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Curiel et al. showed a PD-L1 dependent upregulation of IL-10 and a downregulation of 
IL-12 and IFNγ in ovarian cancer which is similar to our findings in the ascites 
supernatant in this thesis (Curiel et al., 2003). 
 
Evidence of the suppressive capacity of ascites was shown when T cells were cultured in 
varying dilutions of supernatant. Compared to bead stimulated T cells cultured in media 
there was a decrease in proliferation when T cells were cultured in media containing 
ascites supernatant. In particular there was a significant reduction in proliferation of T 
cells when cultured in malignant ascites compared to benign/borderline cases. IL-10 and 
TGF-β in particular were expressed at a significantly higher concentration in ascites from 
patients with malignant cancer compared to patients with benign/borderline cancer. These 
two cytokines are two candidates responsible for the suppression of the T cells cultured in 
the supernatant. We carried out a pilot experiment culturing T cells in ascites supernatant 
and blocking IL-10. No significant improvements in T cell proliferation were observed 
however further experiments may reveal more about the role of IL-10 as well as TGF-β. 
Are they involved in the suppression of the anti-tumour immune response? Or are they 
merely a marker of an immunosuppressed environment? Experiments involving IL-10 
and TGF-β will be discussed later. 
 
Our observation that VEGF was increased in patients’ ascites is in agreement with other 
studies showing VEGF can increase vascular permeability and lead to ascites formation 
(Mesiano et al., 1998). A mouse model of ovarian cancer has shown that blocking VEGF 
with antibodies in vivo leads to an inhibition of tumour cell growth (Mesiano et al., 
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1998). In addition, VEGF along with IL-6 and IL-8 have also been shown to be increased 
in the sera of patients with ovarian cancer compared to healthy controls (Gorelik et al., 
2005). This is in contrast with the results described in this thesis as we couldn’t detect 
any of these cytokines in the plasma of ovarian cancer patients (data not shown). 
However, the implication that VEGF, IL-6 and IL-8 are involved in ovarian cancer agrees 
with the data presented in this thesis and suggests an important involvement of these 
cytokines in the survival and progression of ovarian tumours. 
 
TGF-β was the most highly expressed cytokine in the ascites of patients with malignant 
ovarian cancer in this project. This contrasts with a study carried out be Toutirais et al. in 
which they studied the cytokine content of the media in which seven ovarian cancer cell 
lines were cultured (Toutirais et al., 2003). The authors detected low TGF-β in all of the 
media and could not detect any IL-10. IL-8 and IL-6 were constitutively expressed by 
most of the cell lines, similar to our data and others in other types of tumour where they 
are implicated in promoting tumour growth (Smith et al., 2001; Xie, 2001). Similarly to 
our results, TNF-α, IL-1β, and GM-CSF were either detected at low concentrations or 
undetectable. This study shows similarities with our data but also differences especially 
in TGF-β and IL-10 levels, although when interpreting the data it must be considered that 
Toutirais et al. examined expression of cancer cell lines, of which there were only seven 
and only two of these were established cell lines (IGROV-1 and OVCAR-3). Our data 
was generated from ascites supernatant and the cytokine content could be due to 
expression by other cell types associated with the tumour and not the tumour cells 
themselves. In fact, data generated from the primary tumour via biopsy samples showed 
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high levels of IL-10 in ovarian cancer, which is in agreement with our data (Pisa et al., 
1992). 
 
The data from chapter 3 suggest an involvement of PD-1 pathway in immunosuppression 
in ovarian cancer; however it is far from the only pathway or group of molecules 
involved. We have shown that there are a number of immunosuppressive and pro-
angiogenic cytokines present which may also contribute. In addition there are other cells 
and pathways reported to be involved in tumour suppression. Data from our lab suggest 
that there are a significantly higher number of regulatory T cells in the ascites of patients 
with malignant ovarian cancer than in patients with benign/borderline cancer 
(unpublished data). Regulatory T cells (Tregs) have been shown previously in ovarian 
cancer and correlated with “high death hazard and reduced survival” (Curiel et al., 2004). 
A more recent study linked the expression of PD-L1 on myeloid derived suppressor cells 
associated with a mouse ovarian cancer model to Treg mediated suppression of anti-
tumour immune responses (Liu et al., 2008). This study showed that PD-L1 signalling 
through PD-1 on the Treg surface was involved in their suppressive function. Cancer is 
not the only situation where PD-1 molecules may play a part in Treg function; it has 
previously been shown that PD-L1 is involved in Treg function in foetomaternal 
tolerance. A mouse model of foetomaternal tolerance showed that adoptive transfer of 
Tregs from wild type but not PD-L1 deficient mice into PD-L1 deficient recipients 
significantly improved foetal survival (Habicht et al., 2007). Perhaps the PD-L1 
expression observed in our findings may not be simply interacting with effector T cells to 
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suppress anti-tumour immunity, and a closer look at the PD-1 pathway with Tregs may be 
useful in future. 
 
As alluded to above, myeloid derived suppressor cells (MDSC) may be involved in 
suppression in ovarian cancer. MDSCs have been shown to suppress anti-tumour T cell 
responses in ovarian cancer mediated via arginase I expression (Liu et al., 2009). 
Arginase I is an enzyme commonly found in liver cells which catabolises L-arginine. In 
doing so it has been shown to suppress T cell activity via downregulation of CD3 δ chain 
expression (Rodriguez et al., 2004).  Arginase I expression in this model was controlled 
by PD-1 and CTLA-4 and suppression of these molecules resulted in a reduction in the 
suppressive potential of these MDSCs. 
 
Our lab has also shown expression of IDO in the tumour mass by real time PCR 
(unpublished data). IDO is suppressive to T cells as it catabolises the essential amino acid 
tryptophan and the catabolites it produces are toxic to the T cell (Munn et al., 1998). IDO 
expression dendritic cells have been reported in a wide range of cancers including breast, 
colon, lung and pancreatic cancers (Munn et al., 2002). In addition, Munn and colleagues 
have shown that an inhibitor of IDO, 1-methyltryptophan (1-MT), can significantly delay 
tumour growth in vivo (Munn et al., 2002). This expression in tumour patients combined 
with functional in vivo data in mouse tumour models suggests that IDO expression by 
DCs may be an important mechanism of immunosuppression in the tumour 
microenvironment.  
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Finally recent evidence has suggested another co-stimulatory molecule may be involved 
in the suppression of immune responses in ovarian cancer. B7-H4 is a member of the B7 
family, the ligand of which remains unknown. Its inhibitory role on T cells has been 
shown in experiments which report suppression of T cell proliferation and cytokine 
expression (Prasad et al., 2003; Sica et al., 2003). B7-H4 has been shown to be expressed 
on ovarian tumours and tumour-associated macrophages. B7-H4 expression on 
macrophages correlated inversely with patient outcome (Kryczek et al., 2007). Blockade 
of B7-H4 improved the stimulatory capacity of these macrophages to activate T cells and 
resulted in regression of tumour growth in vivo (Kryczek et al., 2006). Furthermore Tregs 
could stimulate expression of B7-H4 on antigen presenting cells and that B7-H4 
expression on tumour-associated macrophages correlated with Treg numbers in the 
tumour. 
 
Overall it seems that a number of molecules and cells could be playing a part in the 
suppression of the immune response in ovarian cancer and it is limiting to focus on one 
pathway and expect to find a single target for therapy. The PD-1 pathway from our 
results and others is certainly involved in the immunosuppression observed in the 
microenvironment of the tumour however it is clearly not the only player. Although for 
every other pathway and cell type mentioned above as also playing a role, the PD-1 
pathway has been shown to be linked in some way. Further in depth analysis of the 
interplay between these pathways and cells needs to be carried out before effective cancer 
targeting immunotherapies can be designed. 
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5.1. Future Work 
Future work on this project should include a more in depth functional analysis of the roles 
played by IL-10 and TGF-β. Both of these cytokines are expressed significantly higher in 
the ascites supernatant of patients with malignant ovarian cancer compared to patients 
with benign/borderline ovarian cancer. Early functional data suggests that IL-10 may be 
involved in the suppression of T cells in part but not completely although a larger study 
using more supernatants from a wide range of patients would be of greater benefit. 
Greater volumes of supernatant should also be collected to allow repeats of the same 
patients to be carried out, the work using the supernatants presented in this thesis suffer 
from a lack of repeats due to small volumes of supernatant available to us. With the 
ability to repeat the data generated from the same patients stronger conclusions could be 
drawn. 
 
It would be interesting to see the effect of blocking TGF-β on T cell proliferation from a 
larger group of supernatants and the effect of combined blockade. The role of VEGF 
should also be considered for reasons apart from its angiogenic properties. Recombinant 
VEGF has been shown to upregulate PD-L1 on myeloid dendritic cells in vitro and 
should be investigated in the context of this study for its role on PD-L1 expression on 
monocytes (Curiel et al., 2003). 
 
The data shown in this thesis phenotyping the immune cells from patients blood and 
ascites suggests an involvement for the PD-1 pathway in ovarian cancer. However, the 
numbers of patients in this study is low with less than 25 malignant cases and even fewer 
 171 
 
benign/borderline cases. Before more solid conclusions can be drawn from these data, 
more samples need to be collected. Furthermore, maintaining collection of these type of 
data over a longer period will allow analysis regarding prognosis to be carried out. Patient 
stage and grade can be compared with PD-L1 expression on monocytes, or the five year 
survival rate of patients compared to initial PD-L1 expression on monocytes. This will 
give a more comprehensive analysis as to the importance of the role of PD-1 in ovarian 
and the importance of the pathway as a prognostic marker.  
 
A mouse model of ovarian cancer might be of benefit in the future progression of this 
work in terms of the benefit of blocking PD-L1 on ascitic monocytes on the growth of the 
tumour. Ascitic monocytes have been shown to significantly suppress T cell responses in 
this thesis and there is a suggestion that PD-1 blockade may allow T cells to increase 
their proliferation. The relevance of this may be tested in a mouse model of the disease if 
T cells which had been cultured with ascitic monocytes with and without PD-1 blocking 
antibody were adoptively transferred into the animals and the effect on tumour growth 
was measured. 
 
Finally the effect of blocking other inhibitory pathways should be investigated and 
comparisons could be made to the PD-1 pathway. The B7-H4 pathway has been shown to 
be involved in suppression of immune responses in ovarian cancer however no study has 
ever compared the blockade of both pathways or the effect of a combined blockade on 
anti-tumour T cell responses. Blocking the PD-1 pathway in combination with any of the 
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aforementioned suppressive molecules may also be of benefit, these include TGF-β, 
VEGF, IDO or arginase. 
 
Future work will continue in our lab to investigate the role played by MDSC and arginase 
in ovarian cancer. Firstly the markers on human MDSC need to be defined clearly and 
work is starting in this area. Once we are able to identify MDSC populations we can 
phenotype them for PD-1 pathway members as well as isolate them to study arginase 
expression levels. If we can isolate MDSC in a pure form to high numbers functional 
experiments could be carried out to look at the effect they have on T cell proliferation and 
cytokine production, luminex could be performed to characterise the expression of 
cytokines produced by MDSCs and this could be related to the existing data in this thesis 
on cytokine expression in the ascites. In addition we could investigate the potential role 
MDSC have on antigen presenting cells phenotype (PD-L1 expression) and perhaps find 
a correlation between MDSC and Treg numbers. 
 
5.2. Conclusion 
This thesis shows the significance of PD-1 pathway molecule expression on immune cells 
present in ovarian cancer ascites. These findings agree with similar studies in the 
literature and suggest that the PD-1 pathway is a potential target for ovarian cancer 
therapy. These findings also suggest that the PD-1 pathway is not the only target in 
ovarian cancer as we have shown high levels of immunosuppressive cytokines present in 
the tumour microenvironment. Future work on this project should focus on a combined 
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approach to targeting more than one aspect of immunosuppression associated with 
ovarian cancer. 
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Appendix 
 
Gating Strategies 
 
Below details the gating strategies used for figure 3.1 – 3.6 
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Forward scatter and side scatter dot plots were used to gate on granulocytes and 
lymphocytes based on size and granularity. 
 
Isotype antibody controls were run for all fluorochromes used and gates were set based 
on these. Each quadrant of a dot plot was set so that they contained less than 0.5% of the 
gated population except for the bottom left quadrant. An example of isotype gating on 
lymphocytes stained with APC and PE isotypes is shown below. 
 
 
 
